1,3-ditolylguanidine profile

1,3-Ditolylguanidine, also known as DTG, is a organic compound that has been studied for its potential applications in various fields. It is a strong base and is commonly used as a catalyst in organic synthesis. DTG can be synthesized via the reaction of aniline with carbon disulfide and ammonia. Research has shown that DTG exhibits antibacterial and antifungal properties. Additionally, DTG has been investigated for its potential as a corrosion inhibitor for metals. The importance of DTG lies in its versatile applications, including its use as a catalyst, a corrosion inhibitor, and a potential antimicrobial agent. Further studies are underway to explore its full potential and optimize its use in various applications.'

1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	7333
CHEMBL ID	282433
CHEBI ID	92585
SCHEMBL ID	35348
MeSH ID	M0143560

Synonym
LS-14397
HMS3266J18
BRD-K33459542-001-02-5
AKOS015840511
nsc132023
nsc-132023
guanidine, 1,3-di-o-tolyl-
guanidine, n,n'-bis(2-methylphenyl)-
NCI60_004115
1,3-bis(2-methylphenyl)guanidine
nocceler dt
hsdb 5307
soxinol dt
1,3-di-(2-tolyl)guanidine
cns 1001
einecs 202-577-6
1,3-di-o-tolylguanidine
1,3-ditolylguanidine
n,n'-di-o-tolueylguanidine
diorthotolylguanidine
sanceler dt
guanidine, 1,3-di(2-tolyl)-
dtg
vulcafor dotg
nsc 473
ai3-14630
akrochem dotg
dotg accelerator
n,n'-bis(2-methylphenyl)guanidine
vulkacit dotg/c
nsc 132023
brn 2653884
NCGC00024819-01
tocris-0841
1,3-di-o-tolylquanidine
PDSP1_001846
PDSP2_001829
di-o-tolylguanidine
eveite dotg
97-39-2
1,3-di-o-tolyguanidine
1,3-bis(o-tolyl)guanidine
vulkacite dotg
nsc-473
guanidine,n'-bis(2-methylphenyl)-
wln: 1r bmyum & mr b1
vulkacit dotg
guanidine,3-di-o-tolyl-
nsc473
dotg
n,n'-di-o-tolylguanidine
usaf a-6598
1,3-di-o-tolylguanidine, 99%
NCGC00024819-02
MLS001359937
smr001224330
D0953
CHEMBL282433
ditolylguanidine
1,2-bis(2-methylphenyl)guanidine
bdbm50009307
cas_97-39-2
cid_7333
bdbm81982
tol2gdn
NCGC00248806-01
ll2p01i17o ,
unii-ll2p01i17o
ec 202-577-6
HMS3075A17
tox21_200712
dtxcid206606
cas-97-39-2
dtxsid2026606 ,
NCGC00258266-01
FT-0606703
AKOS015916211
rhenogran dotg 70
1,3-di-2-tolylguanidine
n,n'-bis(2-methylphenyl)guanidine [hsdb]
gtpl6685
gtpl6684
[3h]-di-o-tolylguanidine
[3h]dotg
SCHEMBL35348
W-100109
n,n'-di-ortho-tolylguanidine
acrochem dotg
n,n-di-o-tolylguanidine
perkacit dotg
n,n'-bis(2-methylphenyl)guanidine #
n,n'-di-o-toluylguanidine
vanax dotg
d.o.t.g
ekaland dotg
mfcd00008513
sr-01000597454
SR-01000597454-1
CHEBI:92585
1,2-di-(2-tolyl)guanidine
Q426022
HMS3675P07
HMS3411P07
1,3-di-o-tolylguanidine;dtg
trimethylolpropanephosphite
CS-0002933
A858635
1,3-bis(2-o-tolyl)guanidine
HY-14218
F71311
AKOS040758839

Excerpt	Reference	Relevance
" The data indicate that DTG is teratogenic at maternal toxic doses and the NOAELs of DTG for maternal and developmental toxicity are 10 mg/kg bw/day in rats."	( Prenatal developmental toxicity study of the basic rubber accelerator, 1,3-di-o-tolylguanidine, in rats. Ema, M; Fujii, S; Hirose, A; Kamata, E; Matsumoto, M, 2006)	0.33

Excerpt	Reference	Relevance
" The results showed that [(3)H]PB28 and the corresponding unlabelled PB28 had superimposed pharmacodynamic properties."	( Tritium radiolabelling of PB28, a potent sigma-2 receptor ligand: pharmacokinetic and pharmacodynamic characterization. Abate, C; Berardi, F; Colabufo, NA; Contino, M; Ferorelli, S; Inglese, C; Perrone, R, 2008)	0.35

Excerpt	Relevance	Reference
"The effect of dosing guinea pigs with spironolactone (100 mg/kg twice daily for 3 days) upon the sigma recognition site labelled with [3H]-DTG was investigated."	( Spironolactone causes a rapid down regulation of sigma recognition sites in guinea pig brain and liver. Knight, AR; Middlemiss, DN; Wyatt, C, 1991)	0.28
" In vitro protein secretion rates exhibit a dose-response relationship with increases in protein release up to a concentration of 10(-8) to 10(-4) M for various derivatives of bromhexine and 10(-4) M for carbachol."	( Lacrimal secretion stimulants: sigma receptors and drug implications. Barfknecht, CF; Cheng, B; Ignace, CC; Iwai, Y; Newton, RE; Schoenwald, RD; Shirolkar, S; Vidvauns, S; Xia, E, 1993)	0.29
" This potentiation is dose-dependent at doses between 1 and 1000 micrograms/kg, IV but bell-shaped dose-response curves are obtained."	( Effects of low and high doses of selective sigma ligands: further evidence suggesting the existence of different subtypes of sigma receptors. Bergeron, R; Debonnel, G, 1997)	0.3
" We have shown that sigma ligands, such as di(2-tolyl)guanidin (DTG), potentiate dose-dependently, with bell-shaped dose-response curves, the neuronal response of pyramidal neurones to N-methyl-D-aspartate (NMDA) in the CA3 region of the rat dorsal hippocampus."	( Effect of short-term and long-term treatments with sigma ligands on the N-methyl-D-aspartate response in the CA3 region of the rat dorsal hippocampus. Bergeron, R; de Montigny, C; Debonnel, G, 1997)	0.3
" Sulpiride increased the maximum effect afforded by different concentrations of NMDA and shifted the dose-response curve of NMDA to the left (EC50 value from 12."	( Neuroleptics with differential affinities at dopamine D2 receptors and sigma receptors affect differently the N-methyl-D-aspartate-induced increase in intracellular calcium concentration: involvement of protein kinase. Hayashi, T; Kagaya, A; Nishida, A; Shimizu, M; Su, TP; Yamawaki, S, 1999)	0.3
" Males were dosed for a total of 49 days beginning 14 days before mating."	( Reproductive and developmental toxicity screening test of basic rubber accelerator, 1,3-di-o-tolylguanidine, in rats. Ema, M; Hirose, A; Kamata, E; Kimura, E; Matsumoto, M, 2006)	0.33
" Initial pharmacokinetics evaluation indicated an excellent brain exposure following oral dosing in mice, suggesting that further investigation into the use of alkoxyisoxazoles as σ1 ligands for antinociception is warranted."	( Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy. Gao, ZB; Gunosewoyo, H; Liu, T; Pang, T; Shi, JJ; Shi, M; Sun, H; Tang, J; Xu, YZ; Yang, F; Yu, LF; Zhang, W; Zheng, YM, 2016)	0.43

Class	Description
toluenes	Any member of the class of benzenes that is a substituted benzene in which the substituents include one (and only one) methyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
15-lipoxygenase, partial	Homo sapiens (human)	Potency	12.5893	0.0126	10.6917	88.5700	AID887
phosphopantetheinyl transferase	Bacillus subtilis	Potency	100.0000	0.1413	37.9142	100.0000	AID1490
TDP1 protein	Homo sapiens (human)	Potency	26.4722	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	15.9943	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	18.1028	0.0002	21.2231	8,912.5098	AID743035; AID743063
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	15.8489	0.0013	18.0743	39.8107	AID926; AID938
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	60.5378	0.0002	29.3054	16,493.5996	AID743069
flap endonuclease 1	Homo sapiens (human)	Potency	79.4328	0.1337	25.4129	89.1251	AID588795
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	22.3872	0.4256	12.0591	28.1838	AID504891
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	79.4328	0.0316	22.3146	100.0000	AID588579
Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)	Potency	2.5119	0.3162	12.7657	31.6228	AID881
Cellular tumor antigen p53	Homo sapiens (human)	Potency	37.8658	0.0023	19.5956	74.0614	AID651631
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	2.5119	0.0063	8.2350	39.8107	AID881
Guanine nucleotide-binding protein G	Homo sapiens (human)	Potency	1.0000	1.9953	25.5327	50.1187	AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
polyadenylate-binding protein 1	Homo sapiens (human)	IC50 (µMol)	42.9000	4.9100	23.7029	76.1900	AID602259; AID602260
Rev	Human immunodeficiency virus 1	IC50 (µMol)	8.3120	8.3120	8.9205	9.5290	AID434976
Female germline-specific tumor suppressor gld-1	Caenorhabditis elegans	IC50 (µMol)	5.2050	1.4710	4.9614	8.4010	AID2802
Cocaine esterase	Homo sapiens (human)	Ki	0.0890	0.0063	0.9835	8.0000	AID1272497
Integrin beta-1	Homo sapiens (human)	Ki	0.0610	0.0015	0.0221	0.0610	AID448644
Muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Ki	0.7440	0.0001	0.5797	10.0000	AID142720
Cytochrome P450 3A4	Homo sapiens (human)	Ki	0.0890	0.0001	1.4162	9.9000	AID1389812
Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)	Ki	0.0890	0.0001	0.0304	0.1570	AID488107
Muscarinic acetylcholine receptor M2	Rattus norvegicus (Norway rat)	Ki	2.9600	0.0001	0.5890	8.2600	AID142872
Cytochrome P450 2C9	Homo sapiens (human)	Ki	0.0890	0.0003	1.6842	10.0000	AID1389812
Integrin alpha-4	Homo sapiens (human)	Ki	0.0610	0.0015	0.0221	0.0610	AID448644
Sodium-dependent serotonin transporter	Rattus norvegicus (Norway rat)	Ki	0.0639	0.0000	0.7056	10.0000	AID204313
C-8 sterol isomerase	Saccharomyces cerevisiae S288C	Ki	2.0000	0.0000	0.9048	7.1500	AID239296
Delta-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	3.9500	0.0000	0.6068	9.2330	AID149045
Mu-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	3.9500	0.0000	0.3845	8.6000	AID149045
Kappa-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	3.9500	0.0000	0.1868	3.9500	AID149045
Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)	Ki	6.6900	0.0003	0.8666	6.6900	AID157457
Kappa-type opioid receptor	Cavia porcellus (domestic guinea pig)	Ki	0.0710	0.0000	0.2018	6.4240	AID1587563
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	Ki	0.0710	0.0000	0.2786	9.0000	AID1587563
Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)	Ki	6.6900	0.0003	0.6805	6.6900	AID157457
Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)	Ki	6.6900	0.0003	0.7071	6.6900	AID157457
Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)	Ki	6.6900	0.0003	0.8196	6.6900	AID157457
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)	Ki	6.7000	0.0004	0.5490	6.7000	AID239597
Sigma intracellular receptor 2	Homo sapiens (human)	Ki	0.0221	0.0001	0.8360	4.6005	AID1587573; AID1626254; AID1861724
Sigma intracellular receptor 2	Rattus norvegicus (Norway rat)	Ki	0.0572	0.0024	1.1050	9.3000	AID1679116; AID1728290; AID1759955; AID1865087; AID1867872; AID1901324
Sigma non-opioid intracellular receptor 1	Cavia porcellus (domestic guinea pig)	Ki	0.0789	0.0000	0.3385	10.0000	AID1159367; AID1369086; AID1378105; AID1389812; AID1403514; AID1456401; AID1511007; AID1519019; AID1587563; AID1597397; AID1679115; AID1728274; AID1759953; AID1865086; AID1867871; AID1901323; AID280698; AID393184; AID448644; AID488107; AID538759; AID619547; AID675970; AID776368
Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)	Ki	6.6900	0.0003	0.7072	6.6900	AID157457
Vesicular acetylcholine transporter	Rattus norvegicus (Norway rat)	Ki	1.1340	0.0013	0.5622	4.5230	AID674902
Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)	Ki	6.6900	0.0003	0.7072	6.6900	AID157457
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	IC50 (µMol)	0.0360	0.0003	0.7028	5.3660	AID204763
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Ki	0.0848	0.0000	0.4901	10.0000	AID1129882; AID1272497; AID1308619; AID1594271; AID1626255; AID1701184; AID203700; AID203701; AID204153; AID204448; AID204596; AID239105; AID239200; AID239347
Sigma non-opioid intracellular receptor 1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.1816	0.0003	0.5570	4.2000	AID204605; AID204762; AID204763
Sigma non-opioid intracellular receptor 1	Rattus norvegicus (Norway rat)	Ki	0.0945	0.0003	0.2671	5.0700	AID204313; AID437525; AID674895
Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)	Ki	6.6900	0.0003	0.7072	6.6900	AID157457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Kd	0.0211	0.0116	0.0211	0.0382	AID204141; AID204143; AID204595
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Kd1	0.0128	0.0128	0.0128	0.0128	AID204144
Sigma non-opioid intracellular receptor 1	Homo sapiens (human)	Kd2	0.0214	0.0214	0.0214	0.0214	AID204294
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
prostaglandin metabolic process	Cocaine esterase	Homo sapiens (human)
xenobiotic metabolic process	Cocaine esterase	Homo sapiens (human)
catabolic process	Cocaine esterase	Homo sapiens (human)
lipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
phospholipid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
apoptotic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of macrophage derived foam cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell migration	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
prostate gland development	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
regulation of epithelial cell differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of chemokine production	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
positive regulation of keratinocyte differentiation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell cycle	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of growth	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
hepoxilin biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
endocannabinoid signaling pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cannabinoid biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxin A4 biosynthetic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleic acid metabolic process	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Integrin beta-1	Homo sapiens (human)
stress fiber assembly	Integrin beta-1	Homo sapiens (human)
calcium-independent cell-matrix adhesion	Integrin beta-1	Homo sapiens (human)
positive regulation of apoptotic process	Integrin beta-1	Homo sapiens (human)
positive regulation of glutamate uptake involved in transmission of nerve impulse	Integrin beta-1	Homo sapiens (human)
regulation of inward rectifier potassium channel activity	Integrin beta-1	Homo sapiens (human)
regulation of spontaneous synaptic transmission	Integrin beta-1	Homo sapiens (human)
reactive gliosis	Integrin beta-1	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Integrin beta-1	Homo sapiens (human)
establishment of mitotic spindle orientation	Integrin beta-1	Homo sapiens (human)
in utero embryonic development	Integrin beta-1	Homo sapiens (human)
cell migration involved in sprouting angiogenesis	Integrin beta-1	Homo sapiens (human)
positive regulation of neuroblast proliferation	Integrin beta-1	Homo sapiens (human)
phagocytosis	Integrin beta-1	Homo sapiens (human)
cellular defense response	Integrin beta-1	Homo sapiens (human)
cell adhesion	Integrin beta-1	Homo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion molecules	Integrin beta-1	Homo sapiens (human)
leukocyte cell-cell adhesion	Integrin beta-1	Homo sapiens (human)
cell-matrix adhesion	Integrin beta-1	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin beta-1	Homo sapiens (human)
neuroblast proliferation	Integrin beta-1	Homo sapiens (human)
muscle organ development	Integrin beta-1	Homo sapiens (human)
myoblast fusion	Integrin beta-1	Homo sapiens (human)
germ cell migration	Integrin beta-1	Homo sapiens (human)
visual learning	Integrin beta-1	Homo sapiens (human)
regulation of collagen catabolic process	Integrin beta-1	Homo sapiens (human)
positive regulation of fibroblast migration	Integrin beta-1	Homo sapiens (human)
cell migration	Integrin beta-1	Homo sapiens (human)
formation of radial glial scaffolds	Integrin beta-1	Homo sapiens (human)
CD40 signaling pathway	Integrin beta-1	Homo sapiens (human)
cell projection organization	Integrin beta-1	Homo sapiens (human)
lamellipodium assembly	Integrin beta-1	Homo sapiens (human)
B cell differentiation	Integrin beta-1	Homo sapiens (human)
extracellular matrix organization	Integrin beta-1	Homo sapiens (human)
positive regulation of cell migration	Integrin beta-1	Homo sapiens (human)
cell-substrate adhesion	Integrin beta-1	Homo sapiens (human)
receptor internalization	Integrin beta-1	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin beta-1	Homo sapiens (human)
cell-cell adhesion mediated by integrin	Integrin beta-1	Homo sapiens (human)
heterotypic cell-cell adhesion	Integrin beta-1	Homo sapiens (human)
negative regulation of Rho protein signal transduction	Integrin beta-1	Homo sapiens (human)
wound healing, spreading of epidermal cells	Integrin beta-1	Homo sapiens (human)
maintenance of blood-brain barrier	Integrin beta-1	Homo sapiens (human)
positive regulation of GTPase activity	Integrin beta-1	Homo sapiens (human)
sarcomere organization	Integrin beta-1	Homo sapiens (human)
myoblast differentiation	Integrin beta-1	Homo sapiens (human)
negative regulation of neuron differentiation	Integrin beta-1	Homo sapiens (human)
positive regulation of fibroblast growth factor receptor signaling pathway	Integrin beta-1	Homo sapiens (human)
positive regulation of angiogenesis	Integrin beta-1	Homo sapiens (human)
negative regulation of vasoconstriction	Integrin beta-1	Homo sapiens (human)
symbiont entry into host cell	Integrin beta-1	Homo sapiens (human)
mesodermal cell differentiation	Integrin beta-1	Homo sapiens (human)
myoblast fate specification	Integrin beta-1	Homo sapiens (human)
axon extension	Integrin beta-1	Homo sapiens (human)
dendrite morphogenesis	Integrin beta-1	Homo sapiens (human)
leukocyte tethering or rolling	Integrin beta-1	Homo sapiens (human)
regulation of cell cycle	Integrin beta-1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Integrin beta-1	Homo sapiens (human)
cardiac muscle cell differentiation	Integrin beta-1	Homo sapiens (human)
cardiac muscle cell myoblast differentiation	Integrin beta-1	Homo sapiens (human)
cardiac cell fate specification	Integrin beta-1	Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulus	Integrin beta-1	Homo sapiens (human)
basement membrane organization	Integrin beta-1	Homo sapiens (human)
positive regulation of wound healing	Integrin beta-1	Homo sapiens (human)
positive regulation of vascular endothelial growth factor signaling pathway	Integrin beta-1	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Integrin beta-1	Homo sapiens (human)
regulation of synapse pruning	Integrin beta-1	Homo sapiens (human)
negative regulation of anoikis	Integrin beta-1	Homo sapiens (human)
cell-cell adhesion	Integrin beta-1	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
negative regulation of endothelial cell proliferation	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukocyte chemotaxis involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukocyte migration involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene production involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene metabolic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
humoral immune response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of angiogenesis	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
lipoxygenase pathway	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
positive regulation of bone mineralization	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
dendritic cell migration	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
glucose homeostasis	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of fat cell differentiation	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of insulin secretion	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of vascular wound healing	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of wound healing	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of inflammatory response to wounding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of cytokine production involved in inflammatory response	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of cellular response to oxidative stress	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
leukotriene A4 biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
regulation of reactive oxygen species biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of response to endoplasmic reticulum stress	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
negative regulation of sprouting angiogenesis	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
positive regulation of leukocyte adhesion to arterial endothelial cell	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
lipoxin biosynthetic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonic acid metabolic process	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
lipid oxidation	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
immune response in gut-associated lymphoid tissue	Integrin alpha-4	Homo sapiens (human)
cell-matrix adhesion involved in ameboidal cell migration	Integrin alpha-4	Homo sapiens (human)
leukocyte cell-cell adhesion	Integrin alpha-4	Homo sapiens (human)
cell-matrix adhesion	Integrin alpha-4	Homo sapiens (human)
integrin-mediated signaling pathway	Integrin alpha-4	Homo sapiens (human)
B cell differentiation	Integrin alpha-4	Homo sapiens (human)
cell-cell adhesion mediated by integrin	Integrin alpha-4	Homo sapiens (human)
heterotypic cell-cell adhesion	Integrin alpha-4	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Integrin alpha-4	Homo sapiens (human)
endodermal cell differentiation	Integrin alpha-4	Homo sapiens (human)
receptor clustering	Integrin alpha-4	Homo sapiens (human)
negative regulation of vasoconstriction	Integrin alpha-4	Homo sapiens (human)
leukocyte tethering or rolling	Integrin alpha-4	Homo sapiens (human)
diapedesis	Integrin alpha-4	Homo sapiens (human)
axonogenesis involved in innervation	Integrin alpha-4	Homo sapiens (human)
cellular response to cytokine stimulus	Integrin alpha-4	Homo sapiens (human)
negative regulation of protein homodimerization activity	Integrin alpha-4	Homo sapiens (human)
positive regulation of leukocyte tethering or rolling	Integrin alpha-4	Homo sapiens (human)
cellular response to amyloid-beta	Integrin alpha-4	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	Integrin alpha-4	Homo sapiens (human)
neuron projection extension	Integrin alpha-4	Homo sapiens (human)
clathrin-dependent extracellular exosome endocytosis	Integrin alpha-4	Homo sapiens (human)
positive regulation of endothelial cell apoptotic process	Integrin alpha-4	Homo sapiens (human)
positive regulation of T cell migration	Integrin alpha-4	Homo sapiens (human)
cell-cell adhesion	Integrin alpha-4	Homo sapiens (human)
cell adhesion mediated by integrin	Integrin alpha-4	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
renal water homeostasis	Guanine nucleotide-binding protein G	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Guanine nucleotide-binding protein G	Homo sapiens (human)
regulation of insulin secretion	Guanine nucleotide-binding protein G	Homo sapiens (human)
cellular response to glucagon stimulus	Guanine nucleotide-binding protein G	Homo sapiens (human)
cholesterol biosynthetic process	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
cholesterol metabolic process	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
hemopoiesis	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
cholesterol biosynthetic process via desmosterol	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
cholesterol biosynthetic process via lathosterol	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
ossification involved in bone maturation	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
regulation of cell growth	Sigma intracellular receptor 2	Homo sapiens (human)
regulation of intracellular lipid transport	Sigma intracellular receptor 2	Homo sapiens (human)
regulation of intracellular cholesterol transport	Sigma intracellular receptor 2	Homo sapiens (human)
cholesterol homeostasis	Sigma intracellular receptor 2	Homo sapiens (human)
positive regulation of wound healing	Sigma intracellular receptor 2	Homo sapiens (human)
positive regulation of lipoprotein transport	Sigma intracellular receptor 2	Homo sapiens (human)
lipid transport	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nervous system development	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
regulation of neuron apoptotic process	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein homotrimerization	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
methylumbelliferyl-acetate deacetylase activity	Cocaine esterase	Homo sapiens (human)
carboxylesterase activity	Cocaine esterase	Homo sapiens (human)
carboxylic ester hydrolase activity	Cocaine esterase	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
calcium ion binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
lipid binding	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 13S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
arachidonate 15-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
linoleate 9S-lipoxygenase activity	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
C-X3-C chemokine binding	Integrin beta-1	Homo sapiens (human)
magnesium ion binding	Integrin beta-1	Homo sapiens (human)
virus receptor activity	Integrin beta-1	Homo sapiens (human)
fibronectin binding	Integrin beta-1	Homo sapiens (human)
protease binding	Integrin beta-1	Homo sapiens (human)
actin binding	Integrin beta-1	Homo sapiens (human)
integrin binding	Integrin beta-1	Homo sapiens (human)
calcium ion binding	Integrin beta-1	Homo sapiens (human)
protein binding	Integrin beta-1	Homo sapiens (human)
coreceptor activity	Integrin beta-1	Homo sapiens (human)
protein-containing complex binding	Integrin beta-1	Homo sapiens (human)
cadherin binding	Integrin beta-1	Homo sapiens (human)
protein heterodimerization activity	Integrin beta-1	Homo sapiens (human)
cell adhesion molecule binding	Integrin beta-1	Homo sapiens (human)
collagen binding involved in cell-matrix adhesion	Integrin beta-1	Homo sapiens (human)
integrin binding involved in cell-matrix adhesion	Integrin beta-1	Homo sapiens (human)
protein tyrosine kinase binding	Integrin beta-1	Homo sapiens (human)
protein kinase binding	Integrin beta-1	Homo sapiens (human)
laminin binding	Integrin beta-1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
arachidonate 5-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonate 12(S)-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
iron ion binding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
protein binding	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
hydrolase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
arachidonate 8(S)-lipoxygenase activity	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
C-X3-C chemokine binding	Integrin alpha-4	Homo sapiens (human)
fibronectin binding	Integrin alpha-4	Homo sapiens (human)
integrin binding	Integrin alpha-4	Homo sapiens (human)
protein binding	Integrin alpha-4	Homo sapiens (human)
coreceptor activity	Integrin alpha-4	Homo sapiens (human)
metal ion binding	Integrin alpha-4	Homo sapiens (human)
cell adhesion molecule binding	Integrin alpha-4	Homo sapiens (human)
protein antigen binding	Integrin alpha-4	Homo sapiens (human)
G protein activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
adenylate cyclase activator activity	Guanine nucleotide-binding protein G	Homo sapiens (human)
C-8 sterol isomerase activity	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
steroid delta-isomerase activity	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
protein binding	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
identical protein binding	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
cholestenol delta-isomerase activity	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
protein binding	Sigma intracellular receptor 2	Homo sapiens (human)
oxysterol binding	Sigma intracellular receptor 2	Homo sapiens (human)
cholesterol binding	Sigma intracellular receptor 2	Homo sapiens (human)
G protein-coupled opioid receptor activity	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
protein binding	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum	Cocaine esterase	Homo sapiens (human)
endoplasmic reticulum lumen	Cocaine esterase	Homo sapiens (human)
intracellular membrane-bounded organelle	Cocaine esterase	Homo sapiens (human)
nucleus	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
cytoskeleton	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
plasma membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
adherens junction	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
focal adhesion	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
membrane	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
extracellular exosome	Polyunsaturated fatty acid lipoxygenase ALOX15B	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
focal adhesion	Integrin beta-1	Homo sapiens (human)
ruffle membrane	Integrin beta-1	Homo sapiens (human)
ruffle	Integrin beta-1	Homo sapiens (human)
cytoplasm	Integrin beta-1	Homo sapiens (human)
plasma membrane	Integrin beta-1	Homo sapiens (human)
focal adhesion	Integrin beta-1	Homo sapiens (human)
external side of plasma membrane	Integrin beta-1	Homo sapiens (human)
cell surface	Integrin beta-1	Homo sapiens (human)
endosome membrane	Integrin beta-1	Homo sapiens (human)
intercalated disc	Integrin beta-1	Homo sapiens (human)
membrane	Integrin beta-1	Homo sapiens (human)
lamellipodium	Integrin beta-1	Homo sapiens (human)
filopodium	Integrin beta-1	Homo sapiens (human)
neuromuscular junction	Integrin beta-1	Homo sapiens (human)
cleavage furrow	Integrin beta-1	Homo sapiens (human)
ruffle membrane	Integrin beta-1	Homo sapiens (human)
integrin alpha1-beta1 complex	Integrin beta-1	Homo sapiens (human)
integrin alpha2-beta1 complex	Integrin beta-1	Homo sapiens (human)
integrin alpha4-beta1 complex	Integrin beta-1	Homo sapiens (human)
integrin alpha5-beta1 complex	Integrin beta-1	Homo sapiens (human)
integrin alpha6-beta1 complex	Integrin beta-1	Homo sapiens (human)
integrin alpha9-beta1 complex	Integrin beta-1	Homo sapiens (human)
integrin alpha10-beta1 complex	Integrin beta-1	Homo sapiens (human)
integrin alphav-beta1 complex	Integrin beta-1	Homo sapiens (human)
myelin sheath abaxonal region	Integrin beta-1	Homo sapiens (human)
sarcolemma	Integrin beta-1	Homo sapiens (human)
melanosome	Integrin beta-1	Homo sapiens (human)
dendritic spine	Integrin beta-1	Homo sapiens (human)
membrane raft	Integrin beta-1	Homo sapiens (human)
perinuclear region of cytoplasm	Integrin beta-1	Homo sapiens (human)
recycling endosome	Integrin beta-1	Homo sapiens (human)
extracellular exosome	Integrin beta-1	Homo sapiens (human)
synaptic membrane	Integrin beta-1	Homo sapiens (human)
glial cell projection	Integrin beta-1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Integrin beta-1	Homo sapiens (human)
cerebellar climbing fiber to Purkinje cell synapse	Integrin beta-1	Homo sapiens (human)
integrin alpha3-beta1 complex	Integrin beta-1	Homo sapiens (human)
integrin alpha7-beta1 complex	Integrin beta-1	Homo sapiens (human)
integrin alpha8-beta1 complex	Integrin beta-1	Homo sapiens (human)
integrin alpha11-beta1 complex	Integrin beta-1	Homo sapiens (human)
receptor complex	Integrin beta-1	Homo sapiens (human)
focal adhesion	Integrin beta-1	Homo sapiens (human)
synapse	Integrin beta-1	Homo sapiens (human)
integrin complex	Integrin beta-1	Homo sapiens (human)
cell surface	Integrin beta-1	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
extracellular region	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
extracellular space	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nucleoplasm	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
cytosol	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear matrix	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear membrane	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
secretory granule lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
perinuclear region of cytoplasm	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
ficolin-1-rich granule lumen	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
nuclear envelope	Polyunsaturated fatty acid 5-lipoxygenase	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Integrin alpha-4	Homo sapiens (human)
focal adhesion	Integrin alpha-4	Homo sapiens (human)
cell surface	Integrin alpha-4	Homo sapiens (human)
membrane	Integrin alpha-4	Homo sapiens (human)
growth cone	Integrin alpha-4	Homo sapiens (human)
integrin alpha4-beta1 complex	Integrin alpha-4	Homo sapiens (human)
integrin alpha4-beta7 complex	Integrin alpha-4	Homo sapiens (human)
neuronal cell body	Integrin alpha-4	Homo sapiens (human)
extracellular exosome	Integrin alpha-4	Homo sapiens (human)
integrin complex	Integrin alpha-4	Homo sapiens (human)
external side of plasma membrane	Integrin alpha-4	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 1	Rattus norvegicus (Norway rat)
plasma membrane	Guanine nucleotide-binding protein G	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2A	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2B	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2C	Rattus norvegicus (Norway rat)
nuclear envelope	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
endoplasmic reticulum	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
endoplasmic reticulum membrane	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
cytoplasmic vesicle	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
nuclear membrane	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
endoplasmic reticulum	3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase	Homo sapiens (human)
endoplasmic reticulum	Sigma intracellular receptor 2	Homo sapiens (human)
lysosome	Sigma intracellular receptor 2	Homo sapiens (human)
endoplasmic reticulum	Sigma intracellular receptor 2	Homo sapiens (human)
rough endoplasmic reticulum	Sigma intracellular receptor 2	Homo sapiens (human)
plasma membrane	Sigma intracellular receptor 2	Homo sapiens (human)
rough endoplasmic reticulum membrane	Sigma intracellular receptor 2	Homo sapiens (human)
nuclear membrane	Sigma intracellular receptor 2	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 2D	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 3B	Rattus norvegicus (Norway rat)
nuclear envelope	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear inner membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
nuclear outer membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
lipid droplet	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytosol	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
growth cone	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
cytoplasmic vesicle	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
anchoring junction	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
postsynaptic density membrane	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum	Sigma non-opioid intracellular receptor 1	Homo sapiens (human)
endoplasmic reticulum membrane	Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor ionotropic, NMDA 3A	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (294)

Assay ID	Title	Year	Journal	Article
AID229188	Inhibition of specific binding of [3H]3-PPP to sigma binding site in Guinea pig brain membranes	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID204141	Binding constant (Kd) for [3H]DTG binding to Sigma opioid receptor type 1 of guinea pig brain membranes at 1 uM BNIT	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor.
AID1587563	Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain cortex membranes after 120 mins by scintillation counting analysis
AID1308616	Displacement of [3H]-di-o-tolylguanidine from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?
AID156820	In vitro inhibitory activity against [3H]-TCP binding to PCP receptor in guinea pig brain membrane homogenates	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and structure-activity relationships of N,N'-di-o-tolylguanidine analogues, high-affinity ligands for the haloperidol-sensitive sigma receptor.
AID1728290	Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membrane incubated for 120 mins by liquid scintillation counting method relative to control	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Novel σ
AID601799	Displacement of [3H]di-o-toylguanidine from sigma 2 receptor in rat liver homogenates	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis of 7,9-diazabicyclo[4.2.2]decanes as conformationally restricted κ receptor agonists: fine tuning of the dihedral angle of the ethylenediamine pharmacophore.
AID204000	Opioid activity in terms of inhibition of [3H]dihydromorphine binding to opioid receptor mu in rat brain membrane.	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Binding of substituted and conformationally restricted derivatives of N-(3-phenyl-n-propyl)-1-phenyl-2-aminopropane at sigma-receptors.
AID1456402	Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membrane incubated for 120 mins measured for 5 mins by scintillation counting method
AID204596	Binding affinity against sigma receptor of MCF cells	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4- iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells.
AID701946	Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting	2012	Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18	Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor.
AID346278	Displacement of [3H]MK-801 from NMDA receptor in pig brain cortex at 1 uM	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their sigma receptor affinity and cytotoxic activity.
AID222713	Effect on the time required for recovery from coma induced in mice by cerebral concussion at the dose of 10 mg/kg po	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID239597	Affinity for human EMP expressed in ERG2 deficient strain of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine as radioligand	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID157582	Binding affinity towards PCP (1-(1-phenylcyclohexyl)piperidine) receptor.	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Novel 1-phenylcycloalkanecarboxylic acid derivatives are potent and selective sigma 1 ligands.
AID142872	Binding affinity was measured as selectivity for sigma 1 site over muscarinic (M2) receptor at 10 uM in rat using [3H]QN as radioligand	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID1861727	Binding affinity to DOR (unknown origin) assessed as inhibition constant by radioligand binding assay	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1139627	Displacement of [3H]DTG from Wistar Hannover rat liver sigma 2 receptor	2014	Journal of medicinal chemistry, Apr-24, Volume: 57, Issue:8	Novel derivatives of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with improved fluorescent and σ receptors binding properties.
AID297868	Displacement of [3H]DTG from sigma2 receptor in Wistar rat liver membrane in presence of 1 uM [3H]pentazocine	2007	Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19	Design and evaluation of naphthol- and carbazole-containing fluorescent sigma ligands as potential probes for receptor binding studies.
AID204153	Sigma opioid receptor type 1 affinity in guinea pig brain by employing [3H](+)-pentazocine as radioligand.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.
AID1189658	Displacement of [3H]-DTG from sigma 2 receptor guinea pig brain membranes incubated for 120 mins by scintillation counting method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Haloperidol metabolite II prodrug: asymmetric synthesis and biological evaluation on rat C6 glioma cells.
AID1865087	Displacement of [3H]DTG from sigma 2 receptor in rat liver membranes measured after 120 mins by scintillation counting method
AID348127	Selectivity ratio of Ki for sigma 2 receptor in rat liver membrane to Ki for EBP in guinea pig liver membrane	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID204595	Binding affinity against MCF cells in the membrane preparation using radioligand binding assay.	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4- iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells.
AID1587573	Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in human RT4 cell membranes incubated for 120 mins in the presence of sigma1 receptor ligand (+)-pentazocine by scintillation counting method
AID1597395	Displacement of [3H] ifenprodil from GluN2B/GluN1a (unknown origin) expressed in mouse L(tk-) cell membranes incubated for 120 mins by scintillation counting method
AID776366	Selectivity ratio of Ki for sigma-2 receptor in rat liver membrane to Ki for sigma-1 receptor in guinea pig brain cortex membrane	2013	European journal of medicinal chemistry, Nov, Volume: 69	New combination of pharmacophoric elements of potent σ₁ ligands: design, synthesis and σ receptor affinity of aminoethyl substituted tetrahydrobenzothiophenes.
AID737843	Selectivity ratio of Ki for sigma 2 receptor in rat liver membranes to Ki for sigma 1 receptor in guinea pig brain membranes	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Improvement of σ1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones.
AID1594271	Displacement of [3H]-(+)-pentazocine from recombinant human sigma1 receptor expressed in HEK293 cell membranes after 120 mins by microbeta scintillation counting method	2019	Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9	Discovery of a novel class of potent and selective tetrahydroindazole-based sigma-1 receptor ligands.
AID351593	Selectivity ratio of Ki for sigma 1 receptor in guinea pig brain membrane to Ki for sigma 2 receptor in rat liver homogenates	2009	Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10	Synthesis of spirocyclic sigma1 receptor ligands as potential PET radiotracers, structure-affinity relationships and in vitro metabolic stability.
AID448643	Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in rat liver after 180 mins by scintillation counting	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis of sigma receptor ligands with unsymmetrical spiro connection of the piperidine moiety.
AID348122	Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane without cerebellum	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID1308619	Displacement of [3H](+)-Pentazocine from sigma 1 receptor in human RPMI8226 cell membranes	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?
AID753963	Displacement of [3H](+)pentazocine from sigma1 receptor in Dunkin Hartley guinea pig brain membrane after 120 mins by liquid scintillation counting analysis	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and receptor binding studies of novel 4,4-disubstituted arylalkyl/arylalkylsulfonyl piperazine and piperidine-based derivatives as a new class of σ1 ligands.
AID665422	Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver after 180 mins by solid scintillation counting in the presence of (+)-pentazocine	2012	European journal of medicinal chemistry, Jul, Volume: 53	Microwave assisted synthesis of spirocyclic pyrrolidines -σ1 receptor ligands with modified benzene-N-distance.
AID204007	Maximum binding capacity of [3H]DTG to Sigma opioid receptor at a concentration of 5 uM BNIT	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor.
AID142720	Binding affinity was measured as selectivity for sigma-1 site over muscarinic (M1) receptor in rat	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID1193623	Displacement of [3H]-di-o-tolylguanidine from sigma 2 receptor in Sprague-Dawley rat liver membranes after 120 mins by beta counting in presence of (+)-pentazocine	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Synthesis and evaluation of tetrahydroindazole derivatives as sigma-2 receptor ligands.
AID1650557	Displacement of [3H]ifenprodil from human recombinant GluN2B expressed in mouse L(tk-) cell membranes co-expressing GluN1a incubated for 120 mins by scintillation counting method	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.
AID239200	Inhibitory constant against sigma receptor type 2 using 3 nM [3H]ditolylguanidine	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
AID222712	Effect on recovery time for coma induced in mice by cerebral concussion (treated group)	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1597433	Binding affinity to sigma2 receptor in rat liver membranes incubated for 120 mins by liquid scintillation counting method
AID391475	Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Thiophene bioisosteres of spirocyclic sigma receptor ligands. 1. N-substituted spiro[piperidine-4,4'-thieno[3,2-c]pyrans].
AID1650559	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membranes incubated for 120 mins by scintillation counting method	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.
AID1679116	Displacement of [3H]-DTG from Sprague-Dawley rat liver sigma 2 receptor incubated for 120 mins by liquid scintillation counting method	2021	RSC medicinal chemistry, Mar-04, Volume: 12, Issue:2	Synthesis and
AID776368	Displacement of (+)-pentazocine from sigma-1 receptor in guinea pig brain cortex membrane after 120 mins by scintillation counting	2013	European journal of medicinal chemistry, Nov, Volume: 69	New combination of pharmacophoric elements of potent σ₁ ligands: design, synthesis and σ receptor affinity of aminoethyl substituted tetrahydrobenzothiophenes.
AID1597396	Displacement of [3H]-(+)-MK-801 from NMDA PCP binding site in pig brain cortex membrane at 1 uM incubated for 120 mins by scintillation counting method relative to control
AID481107	Displacement of [3H]ditolylguanidine from sigma2 receptor in rat liver membrane	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Conformationally constrained kappa receptor agonists: stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives.
AID1189659	Displacement of [3H]-7-OH-DPAT from dopamine D3 receptor in rat olfactory tubercle by scintillation counting method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Haloperidol metabolite II prodrug: asymmetric synthesis and biological evaluation on rat C6 glioma cells.
AID239105	Inhibitory constant against sigma receptor type 1 using 3 nM [3H]pentazocine	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands.
AID737845	Displacement of [3H](+)-Pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting analysis	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Improvement of σ1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones.
AID204143	Binding constant (Kd) for [3H]DTG binding to Sigma opioid receptor type 1 of guinea pig brain membranes at 5 uM BNIT	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor.
AID73736	Inhibition of electrically stimulated contractions of the isolated guinea pig badder.	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	4-(tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity.
AID438610	Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane after 180 mins by scintillation counting	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Evaluation of spirocyclic 3-(3-fluoropropyl)-2-benzofurans as sigma1 receptor ligands for neuroimaging with positron emission tomography.
AID280698	Displacement of [3H](+)-pentazocine from guinea pig brain sigma 1 receptor	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Novel sigma receptor ligands: synthesis and biological profile.
AID204763	Binding affinity towards sigma receptor binding site 1 using [3H](+)-pentazocine	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID415889	Selectivity for sigma 1 receptor in guinea pig brain membrane over sigma 2 receptor in rat liver membrane	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	1,4-Diazepanes derived from (S)-serine--homopiperazines with improved sigma(1) (sigma) receptor affinity and selectivity.
AID619548	Displacement of [3H]ditolylguanidine from rat liver sigma 2 receptor by scintillation counting	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ₁ receptor affinity.
AID437525	Binding affinity to sigma 1 receptor in rat C6 cells	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Exploring the importance of piperazine N-atoms for sigma(2) receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28).
AID1276972	Displacement of [3H]-DTG from sigma 2 receptor in Wistar hannover rat liver membrane after 120 mins	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Development of sigma-1 (σ1) receptor fluorescent ligands as versatile tools to study σ1 receptors.
AID203851	Relative binding to sigma-2 and sigma-1 type receptors, ratio of Ki	1994	Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2	A new approach to the design of sigma-2-selective ligands: synthesis and evaluation of N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1- pyrrolidinyl)ethylamine-related polyamines at sigma-1 and sigma-2 receptor subtypes.
AID1175440	Displacement of [3H]DTG from sigma2 receptor in guinea pig brain membrane after 120 mins by scintillation counting analysis	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): effects on binding affinity and selectivity for sigma receptors and monoamine transporters.
AID427338	Displacement of [3H]DTG from sigma2 receptor in rat liver membrane by liquid scintillation counting	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.
AID488107	Displacement of [3H](+)-pentazocine from sigma1 opioid receptor from guinea pig brain cortex after 150 mins by scintillation counting	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Synthesis and NMDA receptor affinity of fluorinated dioxadrol analogues.
AID674895	Displacement of (+)-[3H]pentazocine from sigma1 receptor in Sprague-Dawley rat cerebral membrane after 90 mins by liquid scintillation counting	2012	Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16	Syntheses and in vitro evaluation of decalinvesamicol analogues as potential imaging probes for vesicular acetylcholine transporter (VAChT).
AID674896	Displacement of [3H]DTG from sigma2 receptor in Sprague-Dawley rat liver membrane after 90 mins by liquid scintillation counting in presence of pentazocine	2012	Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16	Syntheses and in vitro evaluation of decalinvesamicol analogues as potential imaging probes for vesicular acetylcholine transporter (VAChT).
AID204445	Binding affinity for sigma receptor using [3H](+)-pentazocine in guinea pig brain homogenates	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediam ines as sigma receptor ligands. 1. Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes.
AID1193622	Displacement of (+)-[3H]pentazocine from sigma 1 receptor in guinea pig brain homogenate after 120 mins by beta counting	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Synthesis and evaluation of tetrahydroindazole derivatives as sigma-2 receptor ligands.
AID601795	Displacement of [3H]U69593 from kappa opioid receptor in guinea pig brain membranes after 150 mins by scintillation counting	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis of 7,9-diazabicyclo[4.2.2]decanes as conformationally restricted κ receptor agonists: fine tuning of the dihedral angle of the ethylenediamine pharmacophore.
AID1406154	Displacement of [3H]DTG from sigma2 receptor in rat liver membranes by liquid scintillation counting method	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Neurogenic and neuroprotective donepezil-flavonoid hybrids with sigma-1 affinity and inhibition of key enzymes in Alzheimer's disease.
AID601798	Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain membranes	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis of 7,9-diazabicyclo[4.2.2]decanes as conformationally restricted κ receptor agonists: fine tuning of the dihedral angle of the ethylenediamine pharmacophore.
AID1255977	Displacement of [3H]DTG from sigma2 receptor in rat liver membranes incubated for 120 mins by scintillation counting method in presence of pentazocine	2015	Journal of medicinal chemistry, Nov-12, Volume: 58, Issue:21	Novel Potent N-Methyl-d-aspartate (NMDA) Receptor Antagonists or σ1 Receptor Ligands Based on Properly Substituted 1,4-Dioxane Ring.
AID619549	Selectivity ratio of Ki for guinea pig brain sigma 1 receptor to Ki for rat liver sigma 2 receptor	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ₁ receptor affinity.
AID320558	Displacement of [3H]DTG from sigma 2 receptor in rat liver membrane	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Tritium radiolabelling of PB28, a potent sigma-2 receptor ligand: pharmacokinetic and pharmacodynamic characterization.
AID675971	Displacement of [3H]-di-o-tolyguanidine from rat liver sigma 2 receptor after 180 mins by scintillation counting analysis	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Thiophene bioisosteres of spirocyclic σ receptor ligands: relationships between substitution pattern and σ receptor affinity.
AID675977	Selectivity index, ratio of Ki for guinea pig brain sigma1 receptor to Ki for rat liver sigma2 receptor	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Thiophene bioisosteres of spirocyclic σ receptor ligands: relationships between substitution pattern and σ receptor affinity.
AID346274	Displacement of [3H](+)-pentazocine from opioid sigma1 receptor in guinea pig brain homogenate	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their sigma receptor affinity and cytotoxic activity.
AID1314058	Displacement of [3H]di-o-tolylgluanidine from sigma 2 receptor in rat liver membranes after 2 hrs by scintillation counting	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Oxa-Pictet-Spengler reaction as key step in the synthesis of novel σ receptor ligands with 2-benzopyran structure.
AID1901323	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane by competitive radioligand receptor binding assay
AID1300808	Displacement of [3H](+)-pentazocine from Sigma1 receptor in Dunkin Hartley guinea pig brain membrane after 120 mins by liquid scintillation counting analysis	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	One-pot synthesis and sigma receptor binding studies of novel spirocyclic-2,6-diketopiperazine derivatives.
AID1655192	Displacement of [3H]-Di-o-tolylguanidine from sigma-2 receptor in rat liver membranes after 120 mins by scintillation counting method	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands.
AID1143326	Displacement of [3H]DTG from sigma-2 receptor in rat liver membrane homogenate after 2 hrs by liquid scintillation counting analysis in presence of pentazocine	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Synthesis and structure-activity relationship studies of conformationally flexible tetrahydroisoquinolinyl triazole carboxamide and triazole substituted benzamide analogues as σ2 receptor ligands.
AID427339	Selectivity ratio of Ki for rat sigma1 receptor to Ki for rat sigma2 receptor	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.
AID203982	Displacement of [3H]DTG from sigma opioid receptor of homogenized guinea pig whole brain	1991	Journal of medicinal chemistry, Jun, Volume: 34, Issue:6	Radiosynthesis of sigma receptor ligands for positron emission tomography: 11C- and 18F-labeled guanidines.
AID1511007	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes incubated for 120 mins by solid scintillation counting method	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Discovery of new potent dual sigma receptor/GluN2b ligands with antioxidant property as neuroprotective agents.
AID204313	Sigma opioid receptor type 2 affinity in rat liver by employing [3H]ditolylguanidine as radioligand	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.
AID538760	Displacement of [3H]di-o-tolylguanidine from sigma2 receptor rat liver membranes after 180 mins scintillation counting	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
AID323226	Displacement of [3H]ditolylguanidine from sigma 2 opioid receptor in rat liver	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Synthesis and structure-affinity relationships of novel spirocyclic sigma receptor ligands with furopyrazole structure.
AID1378106	Displacement of [3H]DTG from sigma2 receptor in rat liver membranes after 120 mins by microbeta scintillation counting method	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
AID348125	Antiproliferative activity against human PC3 cells expressing EBP at 100 uM after 48 hrs by MTT assay	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID1129878	Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in guinea pig brain cortex membranes after 120 mins by scintillation counting analysis	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	Synthesis, pharmacological evaluation, and σ1 receptor interaction analysis of hydroxyethyl substituted piperazines.
AID634763	Displacement of [3H]DTG from sigma 2 receptor in rat liver membranes	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Synthesis and binding assays of novel 3,3-dimethylpiperidine derivatives with various lipophilicities as σ₁ receptor ligands.
AID1179609	Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain cortex membranes	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Pyridine analogues of spirocyclic σ₁ receptor ligands.
AID1174074	Displacement of [3H]DTG from sigma2 receptor in rat liver membranes after 180 mins by scintillation counting method	2014	Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23	Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.
AID1415567	Displacement of [3H]-ifenprodil from GluN2B receptor (unknown origin) expressed in mouse L (tk-) cell membranes after 120 mins by scintillation counting method	2017	MedChemComm, May-01, Volume: 8, Issue:5	Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID1453236	Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in guinea pig brain membranes after 120 mins by microbeta scintillation counting method
AID415888	Displacement of [3H]ditolylguanidine from sigma 2 receptor in rat liver membrane by liquid scintillation analyzer	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	1,4-Diazepanes derived from (S)-serine--homopiperazines with improved sigma(1) (sigma) receptor affinity and selectivity.
AID418668	Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane by scintillation analysis	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Dancing of the second aromatic residue around the 6,8-diazabicyclo[3.2.2]nonane framework: influence on sigma receptor affinity and cytotoxicity.
AID1462133	Selectivity index, ratio of Ki for sigma1 receptor in guinea pig brain membranes to Ki for sigma2 receptor in rat liver membranes	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ
AID595908	Displacement of [3H]DTG from sigma 2 receptor in guinea pig brain membranes after 120 mins	2011	Journal of medicinal chemistry, May-26, Volume: 54, Issue:10	Novel potent and selective σ ligands: evaluation of their agonist and antagonist properties.
AID204138	Maximum binding capacity against Sigma opioid receptor type 1 at 0.1 uM BNIT	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor.
AID576853	Displacement of [3H]DTG from sigma 2 receptor in Wistar Hannover rat liver membrane in presence of (+)-pentazocine	2011	Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4	Analogues of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) with added polar functionality and reduced lipophilicity for potential use as positron emission tomography radiotracers.
AID1129880	Displacement of [3H]-DTG from sigma-2 receptor in rat liver homogenates after 120 mins by scintillation counting analysis in presence of (+)-pentazocine	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	Synthesis, pharmacological evaluation, and σ1 receptor interaction analysis of hydroxyethyl substituted piperazines.
AID348128	Cytotoxicity against human PC3 cells assessed as LDH release at 100 uM after 24 hrs relative to untreated control	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID1300809	Displacement of [3H]-DTG from Sigma2 receptor in Sprague-Dawley rat liver membrane after 150 mins by liquid scintillation counting analysis in presence of sigma1 blocker (+)-pentazocine	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	One-pot synthesis and sigma receptor binding studies of novel spirocyclic-2,6-diketopiperazine derivatives.
AID203985	In vitro inhibitory activity against [3H]- (+)-3-PPP binding to Sigma opioid receptor in guinea pig brain membrane homogenates	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and structure-activity relationships of N,N'-di-o-tolylguanidine analogues, high-affinity ligands for the haloperidol-sensitive sigma receptor.
AID1462132	Displacement of [3H]-DTG from sigma2 receptor in rat liver membranes after 120 mins by liquid scintillation counting	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ
AID1189645	Displacement of [3H]-spiperone from dopamine D2 receptor in rat striatum by scintillation counting method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Haloperidol metabolite II prodrug: asymmetric synthesis and biological evaluation on rat C6 glioma cells.
AID1462754	Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex at 1 uM	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.
AID618708	Displacement of [3H]-DTG from sigma 2 receptor in rat liver membrane after 30 mins by radioligand binding assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Arylamides hybrids of two high-affinity σ2 receptor ligands as tools for the development of PET radiotracers.
AID1861723	Binding affinity to sigma 1 receptor (unknown origin) assessed as inhibition constant by radioligand binding assay	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID145106	Binding affinity was measured as selectivity for sigma-1 site over N-methyl-D-aspartate (NMDA) receptor in rat using [3H]CGS-19,755 as radioligand at 10 uM	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID204293	Maximum binding capacity against Sigma opioid receptor type 2 at 0.1 uM BNIT	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor.
AID1389813	Displacement of [3H]DTG from sigma 2 receptor in rat liver membranes measured after 120 mins by scintillation counting method	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis of 3-aza[4.4.3]propellanes with high σ
AID393361	Selectivity ratio of Ki for rat liver sigma 2 receptor to Ki for rat liver sigma 1 receptor	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Substituted benzo[d]oxazol-2(3H)-one derivatives with preference for the sigma1 binding site.
AID1597397	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes incubated for 120 mins by scintillation counting method
AID204294	Binding affinity against Sigma opioid receptor type 2 at 0.1 uM BNIT	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor.
AID1626254	Binding affinity to sigma 2 receptor (unknown origin)	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.
AID222070	Effect on the sleeping time of mice before halothane load (control group);NT means not tested	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1626255	Binding affinity to sigma 1 receptor (unknown origin)	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy.
AID204765	Ratio of the binding affinities for sigma-1 and sigma 2 type receptors, ratio of IC50	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID1861726	Binding affinity to MOR (unknown origin) assessed as inhibition constant by radioligand binding assay	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1129882	Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in human RPMI8226 cell membranes after 120 mins by scintillation counting analysis	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	Synthesis, pharmacological evaluation, and σ1 receptor interaction analysis of hydroxyethyl substituted piperazines.
AID346275	Displacement of [3H]ditolylguanine from opioid sigma2 receptor in rat liver homogenate in presence of (+)-pentazocine	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their sigma receptor affinity and cytotoxic activity.
AID1300810	Selectivity ratio of Ki for Sigma1 receptor in Dunkin Hartley guinea pig brain membrane to Ki for Sigma2 receptor in Sprague-Dawley rat liver membrane	2016	Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11	One-pot synthesis and sigma receptor binding studies of novel spirocyclic-2,6-diketopiperazine derivatives.
AID601796	Displacement of [3H]DAMGO from mu opioid receptor in guinea pig brain membranes	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis of 7,9-diazabicyclo[4.2.2]decanes as conformationally restricted κ receptor agonists: fine tuning of the dihedral angle of the ethylenediamine pharmacophore.
AID233687	Selectivity ratio (Sigma1/Sigma2)	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.
AID438611	Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in rat liver membrane after 180 mins by scintillation counting	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Evaluation of spirocyclic 3-(3-fluoropropyl)-2-benzofurans as sigma1 receptor ligands for neuroimaging with positron emission tomography.
AID776871	Displacement of [3H]-DTG from sigma 2 receptor in Wistar Hannover rat liver membranes	2013	European journal of medicinal chemistry, Nov, Volume: 69	Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ₂ receptors.
AID1519020	Displacement of [3H]di-o-tolylguanidine from sigma2 receptor in rat liver membranes measured after 120 mins by solid scintillation counting method
AID1587564	Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membranes incubated for 120 mins in the presence of sigma1 receptor ligand (+)-pentazocine by scintillation counting method
AID204006	Maximum binding capacity of [3H]DTG to Sigma opioid receptor at a concentration of 1 uM BNIT	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor.
AID1179611	Selectivity ratio of Ki for sigma 2 receptor in rat liver membranes to Ki for sigma 1 receptor in guinea pig brain cortex membranes	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Pyridine analogues of spirocyclic σ₁ receptor ligands.
AID448641	Selectivity ratio of Ki for guinea pig brain sigma 1 receptor to Ki for rat liver sigma 2 receptor	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis of sigma receptor ligands with unsymmetrical spiro connection of the piperidine moiety.
AID1728274	Displacement of [3H]-pentazocine from sigma1 receptor in guinea pig brain membrane incubated for 120 mins by liquid scintillation counting method	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Novel σ
AID239296	Affinity for ERG2 of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine radioligand	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID619547	Displacement of (+)-[3H]pentazocine from guinea pig brain sigma 1 receptor after 180 mins by scintillation counting	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ₁ receptor affinity.
AID1597398	Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membranes incubated for 120 mins by scintillation counting method
AID1594272	Displacement of [3H]-DTG from sigma2 receptor in guinea pig brain membranes after 120 mins in presence of sigma1 antagonist (+)-SKF10047 by microbeta scintillation counting method	2019	Bioorganic & medicinal chemistry, 05-01, Volume: 27, Issue:9	Discovery of a novel class of potent and selective tetrahydroindazole-based sigma-1 receptor ligands.
AID438612	Selectivity ratio of Ki for sigma 2 receptor in rat liver membrane to Ki for sigma 1 receptor in guinea pig brain membrane	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Evaluation of spirocyclic 3-(3-fluoropropyl)-2-benzofurans as sigma1 receptor ligands for neuroimaging with positron emission tomography.
AID665423	Selectivity ratio of Ki for rat sigma 2 receptor to Ki for guinea pig sigma1 receptor	2012	European journal of medicinal chemistry, Jul, Volume: 53	Microwave assisted synthesis of spirocyclic pyrrolidines -σ1 receptor ligands with modified benzene-N-distance.
AID156819	In vitro inhibitory activity against [3H](+)-MK-801 binding to PCP receptor in guinea pig brain membrane homogenates	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and structure-activity relationships of N,N'-di-o-tolylguanidine analogues, high-affinity ligands for the haloperidol-sensitive sigma receptor.
AID1297659	Displacement of [3H]-(+)-Pentazocine from sigma1 receptor in guinea pig brain homogenate incubated for 120 mins by solid scintillation counting analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116	Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.
AID448644	Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain after 180 mins by scintillation counting	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis of sigma receptor ligands with unsymmetrical spiro connection of the piperidine moiety.
AID229186	Inhibition of specific binding of [125I]-PIPAG to sigma binding site in Guinea pig brain membranes	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID1389816	Selectivity ratio of Ki for displacement of [3H]DTG from sigma 2 receptor in rat liver membranes to Ki for displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis of 3-aza[4.4.3]propellanes with high σ
AID1701184	Displacement of [3H]-(+)-pentazocine from human sigma1 receptor expressed in HEK293 cell membranes incubated for 120 mins by liquid scintillation counting method	2020	Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23	EST64454: a Highly Soluble σ
AID1297660	Displacement of [3H]DTG from sigma2 receptor in rat liver homogenate incubated for 120 mins by solid scintillation counting analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116	Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.
AID1272498	Binding affinity to sigma-2 receptor (unknown origin) by radioligand displacement assay	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Role of the phenolic OH moiety of GluN2B-selective NMDA antagonists with 3-benzazepine scaffold.
AID665430	Inhibition of human ERG expressed in CHO cells assessed as remaining activity at 10 uM by fluorescence-based assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Microwave assisted synthesis of spirocyclic pyrrolidines -σ1 receptor ligands with modified benzene-N-distance.
AID204448	Inhibitory activity against sigma receptor isolated from guinea pig brain cortex membrane using [3H]DTG as radioligand	1996	Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1	New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives.
AID595982	Selectivity ratio of Ki for sigma 1 receptor in guinea pig brain membranes to Ki for sigma 2 receptor in guinea pig brain membranes	2011	Journal of medicinal chemistry, May-26, Volume: 54, Issue:10	Novel potent and selective σ ligands: evaluation of their agonist and antagonist properties.
AID1650560	Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membranes incubated for 120 mins in the presence of sigma1 receptor ligand (+)-pentazocine by scintillation counting method	2020	Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2	Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.
AID1159367	Displacement of (+)-pentazocine from sigma1 receptor in guinea pig brain cortex membrane by scintillation counting analysis	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands.
AID256859	Displacement of [3H]DTG from sigma 2 receptor in rat liver membranes	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Methyl substitution on the piperidine ring of N-[omega-(6-methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the sigma(1) receptor.
AID1389812	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes measured after 120 mins by scintillation counting method	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis of 3-aza[4.4.3]propellanes with high σ
AID1867871	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes measured after 120 mins by scintillation counting method	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Synthesis and biological evaluation of conformationally restricted GluN2B ligands derived from eliprodil.
AID204459	Tested in vitro for the concentration required to inhibit specific [3H]DTG radioligand binding to sigma receptor on guinea pig brain membrane	1994	Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2	Synthesis and structure-activity studies of N,N'-diarylguanidine derivatives. N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine: a new, selective noncompetitive NMDA receptor antagonist.
AID203697	Binding affinity towards sigma 1 receptor was determined in guinea pig brain membrane using [3H](+)-pentazocine as radioligand	1994	Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2	A new approach to the design of sigma-2-selective ligands: synthesis and evaluation of N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1- pyrrolidinyl)ethylamine-related polyamines at sigma-1 and sigma-2 receptor subtypes.
AID204764	Ratio of the binding affinities against Sigma receptor type 1 and Sigma receptor type 2	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID776367	Displacement of [3H]DTG from sigma-2 receptor in rat liver membrane after 120 mins by scintillation counting	2013	European journal of medicinal chemistry, Nov, Volume: 69	New combination of pharmacophoric elements of potent σ₁ ligands: design, synthesis and σ receptor affinity of aminoethyl substituted tetrahydrobenzothiophenes.
AID1314060	Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain membranes after 2 hrs by scintillation counting	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Oxa-Pictet-Spengler reaction as key step in the synthesis of novel σ receptor ligands with 2-benzopyran structure.
AID1403514	Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in guinea pig brain cortex membranes incubated for 120 mins measured for 5 mins by scintillation counting method
AID488109	Displacement of [3H]ditolylguanidine from sigma2 opioid receptor from rat brain cortex after 150 mins by scintillation counting	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	Synthesis and NMDA receptor affinity of fluorinated dioxadrol analogues.
AID415887	Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane by liquid scintillation analyzer	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	1,4-Diazepanes derived from (S)-serine--homopiperazines with improved sigma(1) (sigma) receptor affinity and selectivity.
AID1462755	Displacement of [3H](+)-Pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting analysis	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.
AID1262301	Displacement of [3H]-(+)-Pentazocine from sigma1 receptor in guniea pig brain cortex membranes by scintillation counting analysis	2015	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24	Benzo[7]annulene-based GluN2B selective NMDA receptor antagonists: Surprising effect of a nitro group in 2-position.
AID738305	Displacement of [3H]DTG from sigma 2 receptor in Wistar Hannover rat liver membrane by competition binding assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Investigation of σ receptors agonist/antagonist activity through N-(6-methoxytetralin-1-yl)- and N-(6-methoxynaphthalen-1-yl)alkyl derivatives of polymethylpiperidines.
AID1189657	Displacement of [3H]-(+)-pentazocine from sigma 1 receptor guinea pig brain membranes incubated for 150 mins by scintillation counting method	2015	European journal of medicinal chemistry, Jan-27, Volume: 90	Haloperidol metabolite II prodrug: asymmetric synthesis and biological evaluation on rat C6 glioma cells.
AID239347	Affinity for sigma receptor type 1 of guinea pig using [3H]ifenprodil or (+)-[3H]pentazocine radioligand	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.
AID1415570	Displacement of [3H]-di-o-tolylguanidine from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis	2017	MedChemComm, May-01, Volume: 8, Issue:5	Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID204781	Inhibition of [3H]DTG binding to Sigma receptor type 2 in rat liver membrane	2003	Journal of medicinal chemistry, May-22, Volume: 46, Issue:11	Synthesis of chiral 1-[omega-(4-chlorophenoxy)alkyl]-4-methylpiperidines and their biological evaluation at sigma1, sigma2, and sterol delta8-delta7 isomerase sites.
AID295928	Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane	2007	European journal of medicinal chemistry, Oct, Volume: 42, Issue:10	Synthesis of bridged piperazines with sigma receptor affinity.
AID1511009	Selectivity ratio of Ki for sigma1 receptor in guinea pig brain membranes to Ki for sigma2 receptor in rat liver membranes	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Discovery of new potent dual sigma receptor/GluN2b ligands with antioxidant property as neuroprotective agents.
AID1403515	Displacement of [3H]-di-o-tolylguanidine from sigma-2 receptor in rat liver membranes incubated for 120 mins measured for 5 mins by scintillation counting method
AID1318843	Selectivity ratio of Ki for sigma2 receptor in rat liver membranes to Ki for sigma1 receptor in guinea pig brain cortex membranes	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands.
AID1262302	Displacement of [3H]DTG from sigma2 receptor in rat liver membranes by scintillation counting analysis	2015	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24	Benzo[7]annulene-based GluN2B selective NMDA receptor antagonists: Surprising effect of a nitro group in 2-position.
AID1511008	Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membranes in the presence of sigma1 receptor ligand (+)-pentazocine incubated for 120 mins by scintillation counting method	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Discovery of new potent dual sigma receptor/GluN2b ligands with antioxidant property as neuroprotective agents.
AID393184	Displacement of [3H](+)-pentazocine from sigma1 opioid receptor in guinea pig brain by solid scintillation counting	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Relationships between the structure of 6-substituted 6,8-diazabicyclo[3.2.2]nonan-2-ones and their sigma receptor affinity and cytotoxic activity.
AID393186	Displacement of [3H]di-o-tolylguanidine from sigma2 opioid receptor in rat liver by solid scintillation counting	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Relationships between the structure of 6-substituted 6,8-diazabicyclo[3.2.2]nonan-2-ones and their sigma receptor affinity and cytotoxic activity.
AID1519019	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes incubated for 120 mins by solid scintillation counting method
AID1415571	Displacement of [3H](+)-Pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting analysis	2017	MedChemComm, May-01, Volume: 8, Issue:5	Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID203842	Binding affinity towards sigma 2 receptor was determined in rat liver membrane using [3H]DTG as radioligand in presence of dextrallorphan	1994	Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2	A new approach to the design of sigma-2-selective ligands: synthesis and evaluation of N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1- pyrrolidinyl)ethylamine-related polyamines at sigma-1 and sigma-2 receptor subtypes.
AID1420188	Cytotoxicity against human PANC1 cells at 50 uM after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19	New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation.
AID1420180	Cytotoxicity against human SH-SY5Y cells at 50 uM after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19	New piperidine-based derivatives as sigma receptor ligands. Synthesis and pharmacological evaluation.
AID1174674	Displacement of [3H]DTG from rat liver sigma2 receptor by scintillation counting analysis in presence of pentazocine	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	From mixed sigma-2 receptor/P-glycoprotein targeting agents to selective P-glycoprotein modulators: small structural changes address the mechanism of interaction at the efflux pump.
AID1318841	Displacement of [3H]-DTG from sigma2 receptor in rat liver membranes after 120 mins by scintillation counting method	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands.
AID701945	Displacement of [3H]di-o-tolylguanidine from Sigma 2 receptor in rat liver membrane after 120 mins by scintillation counting	2012	Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18	Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor.
AID1318840	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes after 120 mins by scintillation counting method	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Computer-assisted design, synthesis, binding and cytotoxicity assessments of new 1-(4-(aryl(methyl)amino)butyl)-heterocyclic sigma 1 ligands.
AID65112	Binding affinity for sigma-1 site over dopamine (D2) receptor in rat using [3H]spiperone as radioligand	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID1127304	Displacement of [3H]-DTG from sigma 2 receptor in Dunkin Hartley guinea pig membrane after 120 mins by liquid scintillation counting analysis in the presence of sigma 1 receptor blocker (-)-SKF-10047	2014	European journal of medicinal chemistry, May-22, Volume: 79	Synthesis and biological evaluation of a novel sigma-1 receptor antagonist based on 3,4-dihydro-2(1H)-quinolinone scaffold as a potential analgesic.
AID203700	Tested for binding affinity against sigma 1 receptor	1994	Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8	Structural features important for sigma 1 receptor binding.
AID351591	Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane by solid scintillation analysis	2009	Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10	Synthesis of spirocyclic sigma1 receptor ligands as potential PET radiotracers, structure-affinity relationships and in vitro metabolic stability.
AID1865088	Selectivity index, ratio of Ki for displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane to Ki for displacement of [3H]DTG from sigma 2 receptor in rat liver membranes
AID256864	Percentage inhibition of rat C6 glioma cell proliferation mediated by sigma 1 receptor at 50 uM	2005	Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26	Methyl substitution on the piperidine ring of N-[omega-(6-methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the sigma(1) receptor.
AID203831	Binding affinity against sigma 2 receptor	1994	Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8	Structural features important for sigma 1 receptor binding.
AID222711	Effect on recovery time for coma induced in mice by cerebral concussion (control group)	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID418670	Displacement of [3H]1,3-ditolylguanine from sigma 2 receptor in rat liver membrane by solid scintillation analysis	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Dancing of the second aromatic residue around the 6,8-diazabicyclo[3.2.2]nonane framework: influence on sigma receptor affinity and cytotoxicity.
AID391476	Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in rat liver membrane	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Thiophene bioisosteres of spirocyclic sigma receptor ligands. 1. N-substituted spiro[piperidine-4,4'-thieno[3,2-c]pyrans].
AID204772	Binding affinity towards sigma receptor binding site 2 using [3H]DTG of whole rat brain homogenates except cerebellum	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles.
AID772805	Neuroprotective activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide release up to 200 uM after 20 to 24 hrs by Griess assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effects.
AID203986	In vitro inhibitory activity against [3H]DTG binding to Sigma opioid receptor in guinea pig brain membrane homogenates	1990	Journal of medicinal chemistry, Sep, Volume: 33, Issue:9	Synthesis and structure-activity relationships of N,N'-di-o-tolylguanidine analogues, high-affinity ligands for the haloperidol-sensitive sigma receptor.
AID203848	Tested for its binding affinity towards sigma-2 site in rat brain using [3H]DTG as radioligand	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Novel 1-phenylcycloalkanecarboxylic acid derivatives are potent and selective sigma 1 ligands.
AID1462129	Displacement of [3H]-pentazocine from sigma1 receptor in guinea pig brain membranes after 120 mins by liquid scintillation counting	2017	Bioorganic & medicinal chemistry, 09-01, Volume: 25, Issue:17	Chiral-pool synthesis of 1,2,4-trisubstituted 1,4-diazepanes as novel σ
AID280699	Displacement of [3H]DTG rom guinea pig brain sigma 2 receptor	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Novel sigma receptor ligands: synthesis and biological profile.
AID1701185	Displacement of [3H]-DTG from sigma2 receptor in guinea pig brain membranes incubated for 120 mins by liquid scintillation counting method	2020	Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23	EST64454: a Highly Soluble σ
AID1861724	Binding affinity to sigma 2 receptor (unknown origin) assessed as inhibition constant by radioligand binding assay	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID229192	Inhibition of specific binding of [3H]NANM of sigma binding site in Guinea pig brain membranes	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID145095	In vitro concentration required to inhibit specific [3H]MK-801 radioligand binding to N-methyl-D-aspartate (NMDA) receptor on rat brain membrane	1994	Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2	Synthesis and structure-activity studies of N,N'-diarylguanidine derivatives. N-(1-naphthyl)-N'-(3-ethylphenyl)-N'-methylguanidine: a new, selective noncompetitive NMDA receptor antagonist.
AID1054570	Displacement of [3H]DTG from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting	2013	European journal of medicinal chemistry, , Volume: 70	Design, synthesis and receptor affinity of novel conformationally restricted σ ligands based on the [4.3.3]propellane scaffold.
AID149045	Binding affinity was measured as selectivity for sigma-1 site over opioid receptor in rat using [3H]naloxone as radioligand	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID222068	Effect on the sleeping time of mice anesthetized with halothane (treated group);NT means not tested	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1901324	Displacement of [3H]di-O-tolylguanidine from sigma 2 receptor in rat liver membrane by competitive radioligand receptor binding assay
AID1861725	Selectivity index, ratio of Ki for sigma 1 receptor (unknown origin) to Ki for sigma 2 receptor (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID675970	Displacement of [3H]-(+)pentazocine from guinea pig brain sigma 1-type opioid receptor after 120 mins by scintillation counting analysis	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Thiophene bioisosteres of spirocyclic σ receptor ligands: relationships between substitution pattern and σ receptor affinity.
AID701944	Selectivity ratio of Ki for sigma 1 receptor in guinea pig membrane to Ki for sigma 2 receptor in rat liver membrane	2012	Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18	Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor.
AID320561	Displacement of [3H]PB28 from sigma 2 receptor in rat liver membrane	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Tritium radiolabelling of PB28, a potent sigma-2 receptor ligand: pharmacokinetic and pharmacodynamic characterization.
AID1415568	Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 90 mins by scintillation counting method	2017	MedChemComm, May-01, Volume: 8, Issue:5	Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID1175439	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane after 150 mins by scintillation counting analysis	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): effects on binding affinity and selectivity for sigma receptors and monoamine transporters.
AID619550	Displacement of (+)-[3H]MK-801 from pig NMDA receptor PCP binding site at 1 uM	2011	Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19	Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ₁ receptor affinity.
AID295929	Displacement of [3H]ditolylguanidine from sigma 2 receptor in Sprague-Dawley rat liver membrane	2007	European journal of medicinal chemistry, Oct, Volume: 42, Issue:10	Synthesis of bridged piperazines with sigma receptor affinity.
AID203701	Affinity at sigma-1 site by inhibition of [3H](+)-pentazocine (PENT) binding in guinea pig brain	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID600269	Displacement of [3H]-ditolylguanidine from sigma 2 receptor PCP binding site in rat liver membrane	2011	European journal of medicinal chemistry, Jun, Volume: 46, Issue:6	Synthesis of 4-(aminoalkyl) substituted 1,3-dioxanes as potent NMDA and σ receptor antagonists.
AID1159368	Displacement of (+)-DTG from sigma2 receptor in rat liver membrane by scintillation counting analysis	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands.
AID753962	Displacement of [3H]DTG from sigma2 receptor in Sprague-Dawley rat liver membrane after 150 mins by liquid scintillation counting analysis	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and receptor binding studies of novel 4,4-disubstituted arylalkyl/arylalkylsulfonyl piperazine and piperidine-based derivatives as a new class of σ1 ligands.
AID1159370	Selectivity ratio of Ki for guinea pig sigma1 receptor to Ki for rat sigma2 receptor	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Identification, pharmacological evaluation and binding mode analysis of novel chromene and chromane based σ1 receptor ligands.
AID1655191	Displacement of [3H]-(+)pentazocine from sigma-1 receptor in guinea pig brain membranes after 120 mins by scintillation counting method	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands.
AID1378105	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes after 120 mins by microbeta scintillation counting method	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
AID393359	Displacement of [3H](+)-pentazocine from sigma 1 receptor in rat liver membrane	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Substituted benzo[d]oxazol-2(3H)-one derivatives with preference for the sigma1 binding site.
AID1462752	Displacement of [3H]ifenprodil from human NR1-1a/NR2B receptor expressed in Mouse L(tk-) cell membranes incubated for 120 mins by scintillation counting method	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.
AID204762	Compound was evaluated for the binding affinity towards Sigma receptor type 1 using radioligand ([3H]-(+)- Pentazocine) binding assay.	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID1369084	Displacement of [3H]-DTG from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis	2018	Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2	2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists.
AID1759953	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane measured after 120 mins by solid scintillation counting method
AID1462756	Displacement of [3H]-di-o-tolylguanidine from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis	2017	Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20	Replacement of benzylic hydroxy group by vinyl or hydroxymethyl moiety at the 3-benzazepine scaffold retaining GluN2B affinity.
AID538759	Displacement of [3H](+)-pentazocine from sigma1 receptor guinea pig brain after 180 mins scintillation counting	2010	Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22	Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
AID1054572	Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain cortex membranes after 120 mins by scintillation counting	2013	European journal of medicinal chemistry, , Volume: 70	Design, synthesis and receptor affinity of novel conformationally restricted σ ligands based on the [4.3.3]propellane scaffold.
AID1759955	Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membrane by solid scintillation counting method
AID737844	Displacement of [3H]-di-o-tolylguanidine from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Improvement of σ1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones.
AID1511006	Displacement of [3H]ifenprodil from GluN1a/GluN2B (unknown origin) expressed in mouse L(tk-) cell membranes after 120 mins by solid scintillation counting method	2019	European journal of medicinal chemistry, Oct-15, Volume: 180	Discovery of new potent dual sigma receptor/GluN2b ligands with antioxidant property as neuroprotective agents.
AID1453237	Displacement of [3H]DTG from sigma-2 receptor in rat liver membranes after 120 mins by microbeta scintillation counting method
AID427337	Displacement of [3H](+)-pentazocine from sigma1 receptor in rat liver membrane by liquid scintillation counting	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.
AID1867872	Displacement of [3H]-DTG from sigma 2 receptor in rat liver membrane measured after 120 mins by microbeta counting analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Synthesis and biological evaluation of conformationally restricted GluN2B ligands derived from eliprodil.
AID351592	Displacement of [3H]di-o-tolylguanidine from sigma 2 receptor in rat liver homogenates by solid scintillation analysis	2009	Bioorganic & medicinal chemistry, May-15, Volume: 17, Issue:10	Synthesis of spirocyclic sigma1 receptor ligands as potential PET radiotracers, structure-affinity relationships and in vitro metabolic stability.
AID204443	Ability to displace [3H](+)-pentazocine at sigma receptor in guinea pig brain membrane was determined	1993	Journal of medicinal chemistry, Aug-06, Volume: 36, Issue:16	Synthesis and evaluation of conformationally restricted N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at sigma receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds.
AID1272497	Binding affinity to sigma-1 receptor (unknown origin) by radioligand displacement assay	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Role of the phenolic OH moiety of GluN2B-selective NMDA antagonists with 3-benzazepine scaffold.
AID1861728	Binding affinity to KOR (unknown origin) assessed as inhibition constant by radioligand binding assay	2022	Bioorganic & medicinal chemistry letters, 09-15, Volume: 72	Design, synthesis and biological evaluation of novel aminopropylcarboxamide derivatives as sigma ligands.
AID1308615	Displacement of [3H](+)-Pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting analysis	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?
AID1179610	Displacement of [3H]DTG from sigma 2 receptor in rat liver membranes in presence of (+)-pentazocine	2014	Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15	Pyridine analogues of spirocyclic σ₁ receptor ligands.
AID229190	Inhibition of specific binding of [3H]DTG to sigma binding site in Guinea pig brain membranes	1992	Journal of medicinal chemistry, Dec-11, Volume: 35, Issue:25	Radiosynthesis, cerebral distribution, and binding of [125I]-1-(p-iodophenyl)-3-(1-adamantyl)guanidine, a ligand for sigma binding sites.
AID1456401	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membrane incubated for 120 mins measured for 5 mins by scintillation counting method
AID772798	Neuroprotective activity in Sprague-Dawley rat primary microglia cells assessed as inhibition of LPS-stimulated nitric oxide release preincubated for 30 mins followed by LPS challenge measured after 24 hrs by Griess assay	2013	Bioorganic & medicinal chemistry, Oct-01, Volume: 21, Issue:19	N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as σ receptor ligands with potential neuroprotective effects.
AID1174073	Displacement of [3H](+)-pentazocine from sigma1 receptor in guinea pig brain membranes after 180 mins by scintillation counting method	2014	Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23	Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.
AID391478	Selectivity ratio, Ki for sigma 1 receptor in guinea pig brain membrane to Ki for sigma 2 receptor rat liver membrane	2008	Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20	Thiophene bioisosteres of spirocyclic sigma receptor ligands. 1. N-substituted spiro[piperidine-4,4'-thieno[3,2-c]pyrans].
AID1129883	Displacement of [3H]-DTG from sigma-2 receptor in human RT4 cell membranes after 120 mins by scintillation counting analysis in presence of (+)-pentazocine	2014	Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7	Synthesis, pharmacological evaluation, and σ1 receptor interaction analysis of hydroxyethyl substituted piperazines.
AID1679115	Displacement of [3H]-pentazocine from guinea pig brain sigma 1 receptor incubated for 120 mins by liquid scintillation counting method	2021	RSC medicinal chemistry, Mar-04, Volume: 12, Issue:2	Synthesis and
AID203832	The compound was evaluated for affinity at sigma-2 site by inhibition of [3H]1,3-di(2-tolyl)guanidine (DTG) binding in guinea pig brain	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID348123	Displacement of [3H]-DTG from sigma 2-type opioid receptor in rat liver membrane in presence of (+)-pentazocine	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID348121	Displacement of [3H](-)-(S)-emopamil from EBP in guinea pig liver membrane	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID204605	Binding affinity for sigma receptor was evaluated by the inhibitory effect on [3H]DTG to rat whole brain membranes	2000	Journal of medicinal chemistry, Jan-27, Volume: 43, Issue:2	3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.
AID1655193	Displacement of [3H]ifenprodil from GluN2B (unknown origin) expressed in mouse L(tk-) cell membranes co-expressing GluN1a incubated for 120 mins by scintillation counting method	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands.
AID1865086	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane measured after 120 mins by scintillation counting method
AID323225	Displacement of [3H](+)-pentazocine from sigma 1 opioid receptor in guinea pig brain membrane	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Synthesis and structure-affinity relationships of novel spirocyclic sigma receptor ligands with furopyrazole structure.
AID437517	Displacement of [3H]DTG form sigma 2 receptor in Wistar Hannover rat liver membrane by radioreceptor binding assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Exploring the importance of piperazine N-atoms for sigma(2) receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28).
AID204594	Binding affinity against sigma receptor was expressed as Bmax	1994	Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12	Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4- iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells.
AID204144	Binding affinity against Sigma opioid receptor type 1 at 0.1 uM BNIT	2002	Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12	Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor.
AID61496	Binding affinity for sigma-1 site over dopamine receptor D1 in rat using [3H]SCH-23390 as radioligand	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID1175441	Selectivity ratio of Ki for guinea pig brain sigma2 receptor to Ki for guinea pig brain sigma1 receptor	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): effects on binding affinity and selectivity for sigma receptors and monoamine transporters.
AID393360	Displacement of [3H]DTG from sigma 2 receptor in rat liver membrane	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Substituted benzo[d]oxazol-2(3H)-one derivatives with preference for the sigma1 binding site.
AID481104	Displacement of [3H](+)-pentazocine from sigma1 receptor in guinea pig brain membrane	2010	Journal of medicinal chemistry, May-27, Volume: 53, Issue:10	Conformationally constrained kappa receptor agonists: stereoselective synthesis and pharmacological evaluation of 6,8-diazabicyclo[3.2.2]nonane derivatives.
AID616127	Displacement of [3H]-DTG from sigma 2 receptor from rat liver in presence of pantazocine	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Fluorescent derivatives of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a tool for uptake and cellular localization studies in pancreatic tumor cells.
AID595907	Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in guinea pig brain membranes after 150 mins	2011	Journal of medicinal chemistry, May-26, Volume: 54, Issue:10	Novel potent and selective σ ligands: evaluation of their agonist and antagonist properties.
AID157457	Binding affinity was measured as selectivity for sigma-1 site over phencyclidine (PCP) receptor in rat using [3H]TCP as radioligand	1994	Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13	Novel (4-phenylpiperidinyl)- and (4-phenylpiperazinyl)alkyl-spaced esters of 1-phenylcyclopentanecarboxylic acids as potent sigma-selective compounds.
AID674902	Displacement of [125I]O-iodo-trans-decalinvesamicol from VAChT in Sprague-Dawley rat cerebral membrane after 1 hr by gamma counting	2012	Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16	Syntheses and in vitro evaluation of decalinvesamicol analogues as potential imaging probes for vesicular acetylcholine transporter (VAChT).
AID1369086	Displacement of [3H]-(+)-Pentazocine from sigma 1 receptor in guinea pig brain cortex membranes after 120 mins by scintillation counting analysis	2018	Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2	2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists.
AID203824	In vitro binding affinity at opioid sigma-1 receptor in guinea pig brain membranes by (+)-[3H]pentazocine displacement.	2004	Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9	4-(tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity.
AID665421	Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane after 180 mins by solid scintillation counting	2012	European journal of medicinal chemistry, Jul, Volume: 53	Microwave assisted synthesis of spirocyclic pyrrolidines -σ1 receptor ligands with modified benzene-N-distance.
AID204770	Binding affinity towards Sigma receptor site 2 in rat brain using [3H]DTG as radioligand	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines.
AID1054568	Selectivity ratio of Ki for sigma 2 receptor in rat liver membranes to Ki for sigma 1 receptor in guinea pig brain cortex membranes	2013	European journal of medicinal chemistry, , Volume: 70	Design, synthesis and receptor affinity of novel conformationally restricted σ ligands based on the [4.3.3]propellane scaffold.
AID348126	Selectivity ratio of Ki for sigma 1 receptor in guinea pig brain membrane without cerebellum to Ki for EBP in guinea pig liver membrane	2008	Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23	Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	20 (5.73)	18.7374
1990's	186 (53.30)	18.2507
2000's	54 (15.47)	29.6817
2010's	75 (21.49)	24.3611
2020's	14 (4.01)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (0.56%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	355 (99.44%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
acetone methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).	2	1	ketone body; methyl ketone; propanones; volatile organic compound	EC 3.5.1.4 (amidase) inhibitor; human metabolite; polar aprotic solvent
carbon monoxide Carbon Monoxide: Carbon monoxide (CO). A poisonous colorless, odorless, tasteless gas. It combines with hemoglobin to form carboxyhemoglobin, which has no oxygen carrying capacity. The resultant oxygen deprivation causes headache, dizziness, decreased pulse and respiratory rates, unconsciousness, and death. (From Merck Index, 11th ed). carbon monoxide : A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.	2.39	2	carbon oxide; gas molecular entity; one-carbon compound	biomarker; EC 1.9.3.1 (cytochrome c oxidase) inhibitor; human metabolite; ligand; metabolite; mitochondrial respiratory-chain inhibitor; mouse metabolite; neurotoxin; neurotransmitter; P450 inhibitor; probe; signalling molecule; vasodilator agent
3,4-dihydroxyphenylacetic acid 3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.	3.23	6	catechols; dihydroxyphenylacetic acid	human metabolite
formaldehyde paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy	2.39	2	aldehyde; one-carbon compound	allergen; carcinogenic agent; disinfectant; EC 3.5.1.4 (amidase) inhibitor; environmental contaminant; Escherichia coli metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
hydrogen carbonate Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.	2.38	2	carbon oxoanion	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
histamine [no description available]	1.98	1	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
dihydroxyphenylalanine Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.. dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.	1.98	1	hydroxyphenylalanine; non-proteinogenic alpha-amino acid; tyrosine derivative	human metabolite
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	1.98	1	cyclitol; hexol
melatonin [no description available]	2.44	2	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
2-amino-5-phosphonovalerate 2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.	2.38	2	non-proteinogenic alpha-amino acid	NMDA receptor antagonist
7-hydroxy-2-n,n-dipropylaminotetralin 7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation	2	1	tetralins
8-hydroxy-2-(di-n-propylamino)tetralin 8-Hydroxy-2-(di-n-propylamino)tetralin: A serotonin 1A-receptor agonist that is used experimentally to test the effects of serotonin.. 8-OH-DPAT : A tetralin substituted at positions 1 and 7 by hydroxy and dipropylamino groups respectively	2.68	3	phenols; tertiary amino compound; tetralins	serotonergic antagonist
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: structure given in first source; NMDA receptor antagonist	3.08	5
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.	1.97	1	methylpyridines; phenylpyridine; tetrahydropyridine	neurotoxin
3-hydroxybenzylhydrazine 3-hydroxybenzylhydrazine: decarboxylase inhibitor; RN given refers to parent cpd; structure	1.98	1	phenols
homovanillic acid Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.. homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.. homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.	2.39	2	guaiacols; monocarboxylic acid	human metabolite; mouse metabolite
phenytoin [no description available]	2.9	4	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
5-carboxamidotryptamine 5-carboxamidotryptamine: agonist of 5-HT receptor; structure given in first source	2.08	1	tryptamines
7-nitroindazole 7-nitroindazole: an inhibitor of nitric oxide synthase; exhibits anti-nociceptive activity without increasing blood pressure	2	1
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	1.99	1	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.02	1	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	2.13	1	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
biperiden Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.	2	1	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bromhexine Bromhexine: A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744). bromhexine : A substituted aniline that is 2,4-dibromoaniline which is substituted at position 6 by a [cyclohexyl(methyl)amino]methyl group. It is used (as the monohydrochloride salt) as a mucolytic for the treatment of respiratory disorders associated with productive cough (i.e. a cough characterised by the production of sputum).	1.98	1	organobromine compound; substituted aniline; tertiary amino compound	mucolytic
buflomedil buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure	2.02	1	aromatic ketone
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	1.98	1	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carbetapentane carbetapentane: RN given refers to parent cpd	2.92	4	benzenes
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	2.4	2	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	1.99	1	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	1.99	1	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	2.7	3	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	1.98	1	primary amine
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	2	1	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	2	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
2-amino-7-phosphonoheptanoic acid 2-amino-7-phosphonoheptanoic acid: (D)-isomer active as an antagonist of N-methyl-D-aspartate excitation of central neurons; (L)-isomer inactive; RN given refers to cpd without isomeric designation	1.97	1
p-chloroamphetamine p-Chloroamphetamine: Chlorinated analog of AMPHETAMINE. Potent neurotoxin that causes release and eventually depletion of serotonin in the CNS. It is used as a research tool.	1.98	1
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	2.17	1	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	2.03	1
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	1.99	1	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	2.39	2	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
vanoxerine vanoxerine: structure given in first source. vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.	3.26	6	ether; N-alkylpiperazine; organofluorine compound; tertiary amino compound	dopamine uptake inhibitor
gbr 12935 1-[2-(benzhydryloxy)ethyl]-4-(3-phenylpropyl)piperazine : An N-alkylpiperazine that consists of piperazine bearing 2-(benzhydryloxy)ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent and selective inhibitor of dopamine uptake (KD = 5.5 nM in rat striatal membranes).	2.38	2	ether; N-alkylpiperazine; tertiary amino compound	dopamine uptake inhibitor
go 6976 [no description available]	2.01	1	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
gr 89696 GR 89696: a potent & selective kappa opioid receptor agonist; RN given refers to (E)-2-butenedioate(1:1); RN for parent cpd not available 11/92; GR 103545 is the (R)-isomer	2.46	2	acetamides
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	7.41	147	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	2.07	1	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifenprodil ifenprodil: NMDA receptor antagonist	4.2	16	piperidines
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	2.71	3	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
iproniazid [no description available]	2.17	1	carbohydrazide; pyridines
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	1.99	1	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	2.67	3	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.07	1	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
kynurenic acid Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.	1.97	1	monohydroxyquinoline; quinolinemonocarboxylic acid	G-protein-coupled receptor agonist; human metabolite; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist; Saccharomyces cerevisiae metabolite
levallorphan dextrallorphan: RN given refers to (9alpha,13alpha,14alpha)-isomer	2.68	3
mazindol Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.	1.98	1	organic molecular entity
memantine [no description available]	2.5	2	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.	2.17	1	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
ethylmaleimide Ethylmaleimide: A sulfhydryl reagent that is widely used in experimental biochemical studies.	1.98	1	maleimides	anticoronaviral agent; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor; EC 2.7.1.1 (hexokinase) inhibitor
clorgyline Clorgyline: An antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.. clorgyline : An aromatic ether that is the 2,4-dichlorophenyl ether of 3-aminopropan-1-ol in which the nitrogen is substituted by a methyl group and a prop-1-yn-3-yl group. A monoamine oxidase inhibitor, it was formerly used as an antidepressant.	1.99	1	aromatic ether; dichlorobenzene; terminal acetylenic compound; tertiary amino compound	antidepressant; EC 1.4.3.4 (monoamine oxidase) inhibitor
nafoxidine Nafoxidine: An estrogen antagonist that has been used in the treatment of breast cancer.	2.02	1	benzenes; naphthalenes; ring assembly
masoprocol nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)	2.17	1	catechols; lignan; tetrol	antioxidant; ferroptosis inhibitor; geroprotector; plant metabolite
oxidopamine Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.. oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).	2.67	3	benzenetriol; catecholamine; primary amino compound	drug metabolite; human metabolite; neurotoxin
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	2	1	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
fenclonine Fenclonine: A selective and irreversible inhibitor of tryptophan hydroxylase, a rate-limiting enzyme in the biosynthesis of serotonin (5-HYDROXYTRYPTAMINE). Fenclonine acts pharmacologically to deplete endogenous levels of serotonin.	1.98	1	phenylalanine derivative
pentazocine [no description available]	2.58	2	benzazocine
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.38	2	barbiturates	GABAA receptor agonist
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	1.99	1	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	2.39	2	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.	2.11	1	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	1.97	1	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
proadifen Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.	1.98	1	diarylmethane
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	2.39	2	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
raloxifene raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.	2.02	1	1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	2.02	1	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
3,4,4a,10b-tetrahydro-4-propyl-2h,5h-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol 3,4,4a,10b-tetrahydro-4-propyl-2H,5H-(1)benzopyrano(4,3-b)-1,4-oxazin-9-ol: RN given refers to (+/-)-isomer; RN, RRs & structure given in first source	2	1
spiperone Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.	3.49	8	aromatic ketone; azaspiro compound; organofluorine compound; piperidines; tertiary amino compound	alpha-adrenergic antagonist; antipsychotic agent; dopaminergic antagonist; psychotropic drug; serotonergic antagonist
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	3.24	6	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
trifluoperazine [no description available]	2.02	1	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trifluperidol Trifluperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in the treatment of PSYCHOSES including MANIA and SCHIZOPHRENIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p621)	2.44	2	aromatic ketone
vesamicol vesamicol: RN given refers to parent cpd; structure	2.42	2	piperidines
wb 4101 N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine bearing a [(2',6'-dimethoxyphenoxy)ethylamino]methyl group at position 2. An alpha1A-adrenergic selective antagonist.	1.99	1	aromatic ether; benzodioxine; secondary amino compound	alpha-adrenergic antagonist
zotepine zotepine: structure	1.99	1	dibenzothiepine; tertiary amino compound	alpha-adrenergic drug; second generation antipsychotic; serotonergic drug
corticosterone [no description available]	2.02	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
dextroamphetamine Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.	1.98	1	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.	1.97	1	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	2	1	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
dehydroepiandrosterone Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.	2.68	3	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
aspartic acid Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.	2.66	3	aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; mouse metabolite; neurotransmitter
sucrose Saccharum: A plant genus of the family POACEAE widely cultivated in the tropics for the sweet cane that is processed into sugar.	2	1	glycosyl glycoside	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; osmolyte; Saccharomyces cerevisiae metabolite; sweetening agent
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	3.08	5	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
aminopyrine Aminopyrine: A pyrazolone with analgesic, anti-inflammatory, and antipyretic properties but has risk of AGRANULOCYTOSIS. A breath test with 13C-labeled aminopyrine has been used as a non-invasive measure of CYTOCHROME P-450 metabolic activity in LIVER FUNCTION TESTS.. aminophenazone : A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a dimethylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It exhibits analgesic, anti-inflammatory, and antipyretic properties.	2.39	2	pyrazolone; tertiary amino compound	antipyretic; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
tetrabenazine 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.	2.06	1	benzoquinolizine; cyclic ketone; tertiary amino compound
cysteamine Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.	1.98	1	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
methoxamine Methoxamine: An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.. methoxamine : An amphetamine in which the parent 1-phenylpropan-2-amine skeleton is substituted at position 1 with an hydroxy group and the phenyl ring is 2- and 5-substituted with methoxy groups. It is an antihypotensive agent (pressor), an agonist acting directly at alpha-adrenoceptors with selectivity for the alpha-1 adrenoceptor subtype similar to phenylephrine .	1.97	1	amphetamines	alpha-adrenergic agonist; antihypotensive agent
n,n-dimethyltryptamine N,N-Dimethyltryptamine: An N-methylated indoleamine derivative and serotonergic hallucinogen which occurs naturally and ubiquitously in several plant species including Psychotria veridis. It also occurs in trace amounts in mammalian brain, blood, and urine, and is known to act as an agonist or antagonist of certain SEROTONIN RECEPTORS.. N,N-dimethyltryptamine : A tryptamine derivative having two N-methyl substituents on the side-chain.	2.06	1	tryptamine alkaloid; tryptamines
methylene blue Methylene Blue: A compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits GUANYLATE CYCLASE, and has been used to treat cyanide poisoning and to lower levels of METHEMOGLOBIN.. methylene blue : An organic chloride salt having 3,7-bis(dimethylamino)phenothiazin-5-ium as the counterion. A commonly used dye that also exhibits antioxidant, antimalarial, antidepressant and cardioprotective properties.	2	1	organic chloride salt	acid-base indicator; antidepressant; antimalarial; antimicrobial agent; antioxidant; cardioprotective agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 4.6.1.2 (guanylate cyclase) inhibitor; fluorochrome; histological dye; neuroprotective agent; physical tracer
zoxazolamine Zoxazolamine: A uricosuric and muscle relaxant. Zoxazolamine acts centrally as a muscle relaxant, but the mechanism of its action is not understood.	1.98	1	benzoxazole
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	1.99	1	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	4.55	25	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
caramiphen caramiphen: structure	1.98	1	benzenes
triparanol Triparanol: Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts.	2.02	1	stilbenoid	anticoronaviral agent
isoprene isoprene: used in manufacture of ''synthetic'' rubber, butyl rubber; copolymer in production of elastomers; structure. isoprene : A hemiterpene with the formula CH2=C(CH3)CH=CH2; the monomer of natural rubber and a common structure motif to the isoprenoids, a large class of other naturally occurring compounds.	2.03	1	alkadiene; hemiterpene; volatile organic compound	plant metabolite
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	2.67	3	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
diphenylguanidine diphenylguanidine: vulcanization accelerator; RN given refers to parent cpd. 1,3-diphenylguanidine : Guanidine carrying a phenyl substituent on each of the two amino groups. It is used as an accelerator in the rubber industry.	2.38	2	guanidines	allergen
1-naphthylamine 1-Naphthylamine: A suspected industrial carcinogen (and listed as such by OSHA). Its N-hydroxy metabolite is strongly carcinogenic and mutagenic.. naphthylamine : A primary arylamine that is naphthalene substituted by an amino group at unspecified position.. 1-naphthylamine : A naphthylamine that is naphthalene substituted by an amino group at position 1.	1.99	1	naphthylamine	human xenobiotic metabolite
pregnenolone [no description available]	2.39	2	20-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; C21-steroid	human metabolite; mouse metabolite
yohimbine Yohimbine: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of ERECTILE DYSFUNCTION.. yohimbine : An indole alkaloid with alpha2-adrenoceptor antagonist activity. It is produced by Corynanthe johimbe and Rauwolfia serpentina.	2.39	2	methyl 17-hydroxy-20xi-yohimban-16-carboxylate	alpha-adrenergic antagonist; dopamine receptor D2 antagonist; serotonergic antagonist
diphenhydramine hydrochloride Antitussive Agents: Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.. diphenhydramine hydrochloride : The hydrochloride salt of diphenhydramine.	3.49	2	hydrochloride; organoammonium salt	anti-allergic agent; antiemetic; antiparkinson drug; antipruritic drug; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; sedative
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	2	1	indazole
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	2.48	2	1,3-benzoxazoles; mancude organic heterobicyclic parent
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	2.92	4	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
thiazoles [no description available]	2	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
muscarine Muscarine: A toxic alkaloid found in Amanita muscaria (fly fungus) and other fungi of the Inocybe species. It is the first parasympathomimetic substance ever studied and causes profound parasympathetic activation that may end in convulsions and death. The specific antidote is atropine.	2.39	2	monosaccharide
hydrazine diamine : Any polyamine that contains two amino groups.	1.98	1	azane; hydrazines	EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
opipramol Opipramol: A tricyclic antidepressant with actions similar to AMITRIPTYLINE.	2.02	1	dibenzoazepine
n-phenethylpiperidine [no description available]	3.15	5
jervine jervine: teratogen from Veratrum grandiflorum; RN given refers to parent cpd(3beta,23beta)-isomer; structure	2.02	1	piperidines
bicuculline Bicuculline: An isoquinoline alkaloid obtained from Dicentra cucullaria and other plants. It is a competitive antagonist for GABA-A receptors.. bicuculline : A benzylisoquinoline alkaloid that is 6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinoline which is substituted at the 5-pro-S position by a (6R)-8-oxo-6,8-dihydrofuro[3,4-e][1,3]benzodioxol-6-yl group. A light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.	1.98	1	benzylisoquinoline alkaloid; isoquinoline alkaloid; isoquinolines	agrochemical; central nervous system stimulant; GABA-gated chloride channel antagonist; GABAA receptor antagonist; neurotoxin
kainic acid Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.	2.67	3	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	2.91	4	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
dehydroepiandrosterone sulfate Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.. dehydroepiandrosterone sulfate : A steroid sulfate that is the 3-sulfooxy derivative of dehydroepiandrosterone.	1.98	1	17-oxo steroid; steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite; mouse metabolite
phenazocine Phenazocine: An opioid analgesic with actions and uses similar to MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1095)	6.66	42
potassium hydroxide potassium hydroxide: RN given refers to cpd with MF of K-OH	1.97	1	alkali metal hydroxide
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	1.98	1	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.	1.98	1	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
cyclazocine Cyclazocine: An analgesic with mixed narcotic agonist-antagonist properties.	3.23	6
n-methylaspartate N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.	4.42	22	amino dicarboxylic acid; D-alpha-amino acid; D-aspartic acid derivative; secondary amino compound	neurotransmitter agent
quinuclidinyl benzilate [no description available]	2.07	1
n,n-dimethylphenylethylamine N,N-dimethylphenylethylamine: RN given refers to parent cpd	1.98	1	primary amine
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	2.17	1	selegiline; terminal acetylenic compound	geroprotector
dexetimide Dexetimide: A muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. Benzetimide is the (-)-enantimorph of dexetimide.	1.97	1	piperidines
levetimide levetimide: inactive enantiomer of dexetimide	1.97	1
pregnanolone Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.	1.98	1	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
glutamic acid Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.	3.09	5	glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical
sodium azide Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).	2.03	1	inorganic sodium salt	antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen
substance p [no description available]	2.68	3	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
butaclamol [no description available]	2.02	1	amino alcohol; organic heteropentacyclic compound; tertiary alcohol; tertiary amino compound	dopaminergic antagonist
ng-nitroarginine methyl ester NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.	2	1	alpha-amino acid ester; L-arginine derivative; methyl ester; N-nitro compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor
quisqualic acid Quisqualic Acid: An agonist at two subsets of excitatory amino acid receptors, ionotropic receptors that directly control membrane channels and metabotropic receptors that indirectly mediate calcium mobilization from intracellular stores. The compound is obtained from the seeds and fruit of Quisqualis chinensis.	2.9	4	non-proteinogenic alpha-amino acid
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid [no description available]	2.63	2	chromanol; monocarboxylic acid; phenols	antioxidant; ferroptosis inhibitor; neuroprotective agent; radical scavenger; Wnt signalling inhibitor
enkephalin, methionine Enkephalin, Methionine: One of the endogenous pentapeptides with morphine-like activity. It differs from LEU-ENKEPHALIN by the amino acid METHIONINE in position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.	2.39	2
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	1.99	1	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
naftifine naftifine: allylamine der; RN given refers to unlabeled parent cpd. naftifine : A tertiary amine in which the nitrogen is substituted by methyl, alpha-naphthylmethyl, and (1E)-cinnamyl groups. It is used (usually as its hydrochloride salt) for the treatment of fungal skin infections.	2.02	1	allylamine antifungal drug; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; sterol biosynthesis inhibitor
carbizocaine [no description available]	2.02	1
rimcazole rimcazole: RN given refers to (cis)-isomer; structure given in first source	5.38	19	carbazoles
idazoxan Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.	2.4	2	benzodioxine; imidazolines	alpha-adrenergic antagonist
remoxipride Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.	2.39	2	dimethoxybenzene
quinpirole Quinpirole: A dopamine D2/D3 receptor agonist.. quinpirole : A pyrazoloquinoline that is (4aR,8aR)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]quinoline substituted by a propyl group at position 5. It acts as a dopamine agonist.	2.39	2	pyrazoloquinoline	dopamine agonist
preclamol [no description available]	2.38	2	piperidines
fura-2 Fura-2: A fluorescent calcium chelating agent which is used to study intracellular calcium in tissues.	1.98	1
opc 14117 OPC 14117: has both brain function activating effect & protective effect against cerebral ischemia; structure given in first source	2	1
zileuton [no description available]	2.17	1	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
eliprodil 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol : A member of the class of piperidines that is piperidine substituted by a 2-(4-chlorophenyl)-2-hydroxyethyl group at position 1 and by a 4-fluorobenzyl group at position 4.	3.64	8	monochlorobenzenes; monofluorobenzenes; piperidines; secondary alcohol; tertiary amino compound
aptiganel aptiganel: NMDA receptor antagonist used to study the effects of stroke; structure given in first source; RN given refers to hydrochloride	1.98	1	naphthalenes
tenocyclidine tenocyclidine : A tertiary amino compound that consists of cyclohexane having piperidin-1-yl and thiophen-2-yl groups attached at position 1. A dissociative anaesthetic drug with halluccinogenic and stimulant effects. Its effects are similar to those of phencyclidine (PCP, an analogue with the thienyl group replaced by phenyl), but it is rather more potent.	3.23	6	piperidines; tertiary amino compound; thiophenes	central nervous system stimulant; hallucinogen; neuroprotective agent; NMDA receptor antagonist
dioxadrol dioxadrol: See also records for d- and l-forms which are referred to as dexoxadrol and levoxadrol, respectfully	2.41	2	diarylmethane
sertraline Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.	1.99	1	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
selfotel selfotel: a N-methyl-D-aspartate (NMDA) antagonist; used to treat stroke-induced impairment	1.97	1	non-proteinogenic alpha-amino acid
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.38	2	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
fenpropimorph [no description available]	2.02	1	alkylbenzene
bicuculline methiodide [no description available]	1.98	1
way 100635 [no description available]	2.02	1
(3h)2-carbomethoxy-3-(4-fluorophenyl)tropane (1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester: RN given refers to (1R-(exo,exo))-isomer	2.05	1
pregnenolone sulfate pregnenolone sulfate: RN given refers to (3 beta)-isomer	2.39	2	steroid sulfate	EC 2.7.1.33 (pantothenate kinase) inhibitor; human metabolite
u 69593 U 69593: selective ligand for opioid K-receptor. U69593 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of phenylacetic acid and the secodary amino group of (5R,7S,8S)-N-methyl-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]decan-8-amine.	2.05	1	monocarboxylic acid amide; N-alkylpyrrolidine; organic heterobicyclic compound; oxaspiro compound	anti-inflammatory agent; diuretic; kappa-opioid receptor agonist
3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate 3-((3-cholamidopropyl)dimethylammonium)-1-propanesulfonate: a surfactant; structure given in first source	2.41	2	1,1-diunsubstituted alkanesulfonate
alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol: NM refers to free form; BMY 14802-1 is the HCl; structure given in first source	5.34	18	N-arylpiperazine
benzamil [no description available]	1.98	1	guanidines; pyrazines
deoxyglucose Deoxyglucose: 2-Deoxy-D-arabino-hexose. An antimetabolite of glucose with antiviral activity.. deoxyglucose : A deoxyhexose comprising glucose having at least one hydroxy group replaced by hydrogen.	1.98	1
2-aminoperimidine 2-aminoperimidine: inhibits bacterial NhaA Na/H+ antiporters; structure in first source	1.97	1
metaphit metaphit: site-directed acylating agent of phencyclidine receptors in rat brain; structure given in first source	2.94	4
u 99194a (5,6-dimethoxyindan-2-yl)dipropylamine: has 20-fold preference for D3 versus D2 dopamine receptors	2	1
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol: structure in first source	2.11	1	piperidines
n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride: structure given in first source; a sigma receptor ligand	3.6	9
iodosulpride iodosulpride: 125I labeled; selective ligand for brain dopamine receptors; structure given in first source	2	1
dihydrotetrabenazine dihydrotetrabenazine: RN given refers to cpd without isomeric designation	2.06	1	isoquinolines
l 687384 L 687384: a high-affinity sigma receptor ligand	2.68	3
bd 1008 BD 1008: structure in first source	3.49	8	primary amine
pre 084 2-(4-morpholino)ethyl-1-phenylcyclohexane-1-carboxylate: structure given in first source	3.43	7	morpholines
methotrexate [no description available]	2.05	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
4-iodo-n-piperidinoethylbenzamide 4-iodo-N-piperidinoethylbenzamide: a malignant melanoma imaging agent; structure given in first source	2	1	carbonyl compound; organohalogen compound
n-(2-(diethylamino)ethyl)-4-iodobenzamide N-(2-(diethylamino)ethyl)-4-iodobenzamide: RN refers to unlabled cpd	2	1
bd 737 BD 737: structure given in first source; BD737 and 738 are enantiomers; have high affinity for sigma receptors	2.39	2
4-chloro-2-(2-imidazolin-2-ylamino)isoindoline 4-chloro-2-(2-imidazolin-2-ylamino)isoindoline: acts as partial agonist at the postsynaptic alpha-adrenoreceptors of the rat anococcygeus muscle & as antagonist at the presynaptic alpha-adrenoreceptors of the rat vas deferens	1.99	1
n-(3-phenyl-n-propyl)-1-phenyl-2-aminopropane N-(3-phenyl-n-propyl)-1-phenyl-2-aminopropane: sigma receptor ligand	1.99	1
n-(n-benzylpiperidin-4-yl)-4-iodobenzamide N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: structure given in first source	1.98	1	piperidines
ethylketocyclazocine Ethylketocyclazocine: A kappa opioid receptor agonist. The compound has analgesic action and shows positive inotropic effects on the electrically stimulated left atrium. It also affects various types of behavior in mammals such as locomotion, rearing, and grooming.	1.97	1
besonprodil besonprodil: CI-1041 is also known as PD19680; NMDA receptor antagonist for treatment of Parkinson's disease; structure in first source	2.13	1
ym 09151-2 nemonapride: structure in first source; RN given refers to compound with no isomeric designation. nemonapride : A racemate composed of (2S,3S)- and (2R,3R)-enantiomers of nemonapride. Highly potent dopamine D2-like receptor antagonist; selective over D1-like receptors (Ki values are 0.1 and 740 nM for D2-like and D1-like receptors respectively). Also potent 5-HT1A receptor agonist (IC50 = 34 nM) and has affinity for sigma receptors.. (2R,3R)-nemonapride : An optically active form of nemonapride having (2R,3R)-configuration.	2.39	2	N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide
opc 4392 OPC 4392: agonist of presynaptic dopamine D(2) receptor; structure given in first source	2	1
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	1.98	1	amino acid zwitterion; angiotensin II	human metabolite
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	2.38	2
dizocilpine [no description available]	2.95	4	secondary amino compound; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
esketamine esketamine : The S- (more active) enantiomer of ketamine.	2.47	2	ketamine	analgesic; intravenous anaesthetic; NMDA receptor antagonist
bd 1047 N-(2-(3,4-Dichlorphenyl)ethyl)-N,N',N'-trimethyl-1,2-ethandiamin: sigma receptor ligand; putative sigma receptor antagonist with antidystonic activity	3.52	8	primary amine
preclamol [no description available]	2.02	1
ibogaine Ibogaine: One of several indole alkaloids extracted from Tabernanthe iboga, Baill. It has a complex pharmacological profile, and interacts with multiple systems of neurotransmission. Ibogaine has psychoactive properties and appears to modulate tolerance to opiates.. ibogaine : An organic heteropentacyclic compound that is ibogamine in which the indole hydrogen para to the indole nitrogen has been replaced by a methoxy group.	2.01	1
pentazocine Pentazocine: The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)	6.77	78	benzazocine
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	3.44	7	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
bd 1063 [no description available]	2.42	2	primary amine
thyrotropin-releasing hormone PR 546: no other info available 9/89. protirelin : A tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence.	2	1	peptide hormone; tripeptide	human metabolite
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	1.98	1	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
enclomiphene Enclomiphene: The trans or (E)-isomer of clomiphene.	2.02	1
zuclomiphene Zuclomiphene: The cis or (Z)-isomer of clomiphene.	2.02	1	stilbenoid
terbinafine [no description available]	2.02	1	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
tamoxifen [no description available]	2.02	1	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
raclopride Raclopride: A substituted benzamide that has antipsychotic properties. It is a dopamine D2 receptor (see RECEPTORS, DOPAMINE D2) antagonist.	2.69	3	salicylamides
dexoxadrol [no description available]	3.9	11
4-phenyl-1-(4-phenylbutyl)piperidine 4-phenyl-1-(4-phenylbutyl)piperidine: a potent ligand for sigma receptors; structure given in first source	2.08	1	piperidines
u-50488 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer: A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21). U50488 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of 3,4-dichlorophenylacetic acid and the secondary amino group of (1R,2R)-N-methyl-2-(pyrrolidin-1-yl)cyclohexanamine	3.29	6	dichlorobenzene; monocarboxylic acid amide; N-alkylpyrrolidine	analgesic; antitussive; calcium channel blocker; diuretic; kappa-opioid receptor agonist
6-cyano-7-nitroquinoxaline-2,3-dione 6-Cyano-7-nitroquinoxaline-2,3-dione: A potent excitatory amino acid antagonist with a preference for non-NMDA iontropic receptors. It is used primarily as a research tool.	2.4	2	quinoxaline derivative
fg 9041 FG 9041: structure given in first source	1.98	1	quinoxaline derivative
sm 21 SM 21: RN given for (3(R)-endo)-isomer and maleate salt; structure in first source	2	1	monocarboxylic acid
ac 915 AC 915: binds sigma(1) opioid receptors; structure in first source	2.02	1
alprostadil [no description available]	2	1	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
nalorphine Nalorphine: A narcotic antagonist with some agonist properties. It is an antagonist at mu opioid receptors and an agonist at kappa opioid receptors. Given alone it produces a broad spectrum of unpleasant effects and it is considered to be clinically obsolete.	1.98	1	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	3.11	5	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	2.95	4	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
preclamol preclamol: centrally acting dopamine receptor agonist with selectivity for autoreceptors	5.14	46
gr 218231 GR 218231: a dopamine D3 receptor antagonist; structure in first source	2	1
fluvoxamine Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.	2.42	2	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
levorphanol Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.	1.97	1	morphinane alkaloid
levallorphan Levallorphan: An opioid antagonist with properties similar to those of NALOXONE; in addition it also possesses some agonist properties. It should be used cautiously; levallorphan reverses severe opioid-induced respiratory depression but may exacerbate respiratory depression such as that induced by alcohol or other non-opioid central depressants. (From Martindale, The Extra Pharmacopoeia, 30th ed, p683)	2.68	3	morphinane alkaloid
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	2.92	4	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	3.86	12	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
dextrorphan Dextrorphan: Dextro form of levorphanol. It acts as a noncompetitive NMDA receptor antagonist, among other effects, and has been proposed as a neuroprotective agent. It is also a metabolite of DEXTROMETHORPHAN.	1.97	1	morphinane alkaloid
fumarates Fumarates: Compounds based on fumaric acid.. fumarate(2-) : A C4-dicarboxylate that is the E-isomer of but-2-enedioate(2-)	2	1	butenedioate; C4-dicarboxylate	human metabolite; metabolite; Saccharomyces cerevisiae metabolite
enkephalin, ala(2)-mephe(4)-gly(5)- [no description available]	2.41	1	peptide
norbinaltorphimine norbinaltorphimine: kappa opiate receptor antagonist; structure given in first source	2.05	1	isoquinolines
pregabalin Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.	2.13	1	gamma-amino acid	anticonvulsant; calcium channel blocker
naltrindole naltrindole: delta opioid receptor antagonist	2.41	1	isoquinolines
phentolamine [no description available]	2.08	1
tetrodotoxin Tetrodotoxin: An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order TETRAODONTIFORMES, which are eaten. The toxin causes paresthesia and paralysis through interference with neuromuscular conduction.. tetrodotoxin : A quinazoline alkaloid that is a marine toxin isolated from fish such as puffer fish. It has been shown to exhibit potential neutotoxicity due to its ability to block voltage-gated sodium channels.	2.44	2	azatetracycloalkane; oxatetracycloalkane; quinazoline alkaloid	animal metabolite; bacterial metabolite; marine metabolite; neurotoxin; voltage-gated sodium channel blocker
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	4.58	26	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
bm 15766 BM 15766: 7-dehydrocholesterol reductase antagonist	2.02	1
igmesine [no description available]	4	14
kb 5492 [no description available]	2.67	3
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(-)-isomer [no description available]	2.06	1	acetamides
morphinans Morphinans: Compounds based on a partially saturated iminoethanophenanthrene, which can be described as ethylimino-bridged benzo-decahydronaphthalenes. They include some of the OPIOIDS found in PAPAVER that are used as ANALGESICS.	1.96	1	isoquinoline alkaloid fundamental parent; morphinane alkaloid
ergoline Ergolines: A series of structurally-related alkaloids that contain the ergoline backbone structure.. ergoline : An indole alkaloid whose structural skeleton is found in many naturally occurring and synthetic ergolines which are known to bind to neurotransmitter receptors, such as dopamine, noradrenaline and serotonin receptors and function as unselective agonists or antagonists at these receptors.	1.97	1	diamine; ergoline alkaloid; indole alkaloid fundamental parent; indole alkaloid; organic heterotetracyclic compound
enkephalin, leucine-2-alanine Enkephalin, Leucine-2-Alanine: A delta-selective opioid (ANALGESICS, OPIOID). It can cause transient depression of mean arterial blood pressure and heart rate.	1.98	1
lu 28-179 Lu 28-179: sigma(2) ligand and lysosomotropic agent; structure in first source	3.14	5
ne 100 [no description available]	3.16	5
sm 346 SM 346: 2-mercaptobenzimidazole derivative	2.06	1
sa 4503 [no description available]	2.11	1
1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride SA 4503: a sigma(1) receptor agonist; structure in first source	2.92	4
1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene 1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene: a 5-HT2C agonist and 5-HT2A,2B antagonist; RN refers to (trans)-isomer; a phenylaminotetralin; structure given in first source	1.98	1
LSM-1328 [no description available]	2.08	1	sesquiterpenoid
substance p [no description available]	2.39	2
PB28 PB28 : A member of the class of tetralins that is tetralin that is substituted by 3-(4-cyclohexylpiperazin-1-yl)propyl and methoxy groups at positions 1 and 5, respectively. It is a sigma 2 (sigma2) receptor agonist (Ki = 0.68 nM) and exhibits antineoplastic and anti SARS-CoV-2 activities.	3.92	12	aromatic ether; piperazines; tetralins	anticoronaviral agent; antineoplastic agent; apoptosis inducer; sigma-2 receptor agonist
oxadiazoles Oxadiazoles: Compounds containing five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom which exist in various regioisomeric forms.	1.97	1
brimonidine tartrate Brimonidine Tartrate: A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.	1.97	1
veratridine Veratridine: A benzoate-cevane found in VERATRUM and Schoenocaulon. It activates SODIUM CHANNELS to stay open longer than normal.	1.97	1
scopolamine hydrobromide [no description available]	2.68	3
levoxadrol [no description available]	1.97	1
etoxadrol etoxadrol: was heading 1975-94 (see under PIPERIDINES 1975-90); use PIPERIDINES to search ETOXADROL 1975-90; dissociative anesthetic with some cardiovascular effects	2.49	2	ketal
neuropeptide y Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.	3.08	5
florbenazine f 18 florbenazine F 18: a PET tracer; structure in first source	2.06	1
butaclamol Butaclamol: A benzocycloheptapyridoisoquinolinol that has been used as an antipsychotic, especially in schizophrenia.	1.98	1
piperidines Piperidines: A family of hexahydropyridines.	5.35	57
e-52862 [no description available]	3.07	4
sk&f 10047 [no description available]	2.68	3
wms 1410 [no description available]	3.22	5
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.63	2	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
2'-hydroxy-5,9-dimethyl-2-allyl-6,7-benzomorphan SK&F 10047: pharmacologic action of cpd may depend on (L)- or (D)-isomerism; RN given refers to cpd without isomeric designation	6.66	42
okadaic acid Okadaic Acid: A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. It is produced by DINOFLAGELLATES and causes diarrhetic SHELLFISH POISONING.. okadaic acid : A polycyclic ether that is produced by several species of dinoflagellates, and is known to accumulate in both marine sponges and shellfish. A polyketide, polyether derivative of a C38 fatty acid, it is one of the primary causes of diarrhetic shellfish poisoning (DSP). It is a potent inhibitor of specific protein phosphatases and is known to have a variety of negative effects on cells.	1.98	1	ketal
peptide yy Peptide YY: A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion.. peptide YY : A 36-membered human gut polypeptide consisting of Tyr, Pro, Ile, Lys, Pro, Glu, Ala, Pro, Gly, Glu, Asp, Ala, Ser, Pro, Glu, Glu, Leu, Asn, Arg, Tyr, Tyr, Ala, Ser, Leu, Arg, His, Tyr, Leu, Asn, Leu, Val, Thr, Arg, Gln, Arg and Tyr-NH2 residues joined in sequence.	2.39	2
cyclic gmp Cyclic GMP: Guanosine cyclic 3',5'-(hydrogen phosphate). A guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. It is a cellular regulatory agent and has been described as a second messenger. Its levels increase in response to a variety of hormones, including acetylcholine, insulin, and oxytocin and it has been found to activate specific protein kinases. (From Merck Index, 11th ed). 3',5'-cyclic GMP : A 3',5'-cyclic purine nucleotide in which the purine nucleobase is specified as guanidine.	2.4	2	3',5'-cyclic purine nucleotide; guanyl ribonucleotide	Escherichia coli metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite
guanosine diphosphate Guanosine Diphosphate: A guanine nucleotide containing two phosphate groups esterified to the sugar moiety.	2.42	2	guanosine 5'-phosphate; purine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.91	4	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	2.41	2	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
guanylyl imidodiphosphate Guanylyl Imidodiphosphate: A non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+. The nucleotide is a potent stimulator of ADENYLYL CYCLASES.. guanosine 5'-[beta,gamma-imido]triphosphate : A nucleoside triphosphate analogue that is GTP in which the oxygen atom bridging the beta- to the gamma- phosphate is replaced by a nitrogen atom A non-hydrolyzable analog of GTP, it binds tightly to G-protein in the presence of Mg(2+).	1.97	1	nucleoside triphosphate analogue
guanosine 5'-o-(2-thiodiphosphate) [no description available]	2.42	2	nucleoside diphosphate analogue

Condition	Relationship Strength	Studies
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.67	3
Breast Cancer [description not available]	1.98	1
Breast Neoplasms Tumors or cancer of the human BREAST.	1.98	1
Heart Disease, Ischemic [description not available]	1.98	1
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	1.98	1
Cerebral Concussion [description not available]	2	1
Brain Concussion A nonspecific term used to describe transient alterations or loss of consciousness following closed head injuries. The duration of UNCONSCIOUSNESS generally lasts a few seconds, but may persist for several hours. Concussions may be classified as mild, intermediate, and severe. Prolonged periods of unconsciousness (often defined as greater than 6 hours in duration) may be referred to as post-traumatic coma (COMA, POST-HEAD INJURY). (From Rowland, Merritt's Textbook of Neurology, 9th ed, p418)	2	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	3.7	10
Ache [description not available]	3.16	5
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	3.16	5
Carcinoma, Small Cell Lung [description not available]	2.05	1
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	2.05	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Nerve Pain [description not available]	2.05	1
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	2.05	1
Cancer of Pancreas [description not available]	2.06	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.06	1
Allodynia [description not available]	2.06	1
Benign Neoplasms [description not available]	2.42	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.42	2
Nociceptive Pain Dull or sharp aching pain caused by stimulated NOCICEPTORS due to tissue injury, inflammation or diseases. It can be divided into somatic or tissue pain and VISCERAL PAIN.	2.1	1
Glial Cell Tumors [description not available]	2.91	4
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.91	4
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.42	7
Acute Confusional Senile Dementia [description not available]	2.43	2
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.43	2
Cancer of Prostate [description not available]	2.31	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.31	1
Congenital Zika Syndrome [description not available]	2.25	1
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Binge Alcohol Consumption [description not available]	2.25	1
Acute Brain Injuries [description not available]	2.52	2
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	2.52	2
Apoplexy [description not available]	2.05	1
Cerebral Ischemia [description not available]	3.12	5
Nerve Degeneration Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.	2.44	2
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	3.12	5
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.05	1
Metabolic Acidosis [description not available]	2.06	1
Acidosis A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.	2.06	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	3.39	7
Encephalopathy, Toxic [description not available]	2.08	1
Pyrexia [description not available]	2.08	1
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	2.08	1
Hypothermia, Accidental [description not available]	2.01	1
Hypothermia Lower than normal body temperature, especially in warm-blooded animals.	2.01	1
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.68	3
Weight Reduction [description not available]	2.43	2
Anal Atresia [description not available]	2.03	1
Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.	2.43	2
Weight Loss Decrease in existing BODY WEIGHT.	2.43	2
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.03	1
Brain Inflammation [description not available]	2.03	1
Astrocytosis [description not available]	2.03	1
Encephalitis Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.	2.03	1
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.03	1
Cleft Palate, Isolated [description not available]	2.03	1
Fetal Death Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.	2.03	1
Congenital Hand Deformities [description not available]	2.03	1
Cleft Palate Congenital fissure of the soft and/or hard palate, due to faulty fusion.	2.03	1
Weight Gain Increase in BODY WEIGHT over existing weight.	2.03	1
Mydriasis Dilation of pupils to greater than 6 mm combined with failure of the pupils to constrict when stimulated with light. This condition may occur due to injury of the pupillary fibers in the oculomotor nerve, in acute angle-closure glaucoma, and in ADIE SYNDROME.	2.03	1
Brain Disorders [description not available]	1.98	1
MPTP Neurotoxicity Syndrome [description not available]	1.98	1
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	1.98	1
Fistula Abnormal communication most commonly seen between two internal organs, or between an internal organ and the surface of the body.	1.98	1
Anoxia, Brain [description not available]	1.98	1
Fasting Hypoglycemia HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.	1.98	1
Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH.	1.98	1
Amnesia-Memory Loss [description not available]	3.08	5
Amnesia Pathologic partial or complete loss of the ability to recall past experiences (AMNESIA, RETROGRADE) or to form new memories (AMNESIA, ANTEROGRADE). This condition may be of organic or psychologic origin. Organic forms of amnesia are usually associated with dysfunction of the DIENCEPHALON or HIPPOCAMPUS. (From Adams et al., Principles of Neurology, 6th ed, pp426-7)	3.08	5
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	2.67	3
Ataxia Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.	1.98	1
Emesis [description not available]	2.38	2
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	2.38	2
Dystonia An attitude or posture due to the co-contraction of agonists and antagonist muscles in one region of the body. It most often affects the large axial muscles of the trunk and limb girdles. Conditions which feature persistent or recurrent episodes of dystonia as a primary manifestation of disease are referred to as DYSTONIC DISORDERS. (Adams et al., Principles of Neurology, 6th ed, p77)	3.24	6
Gastric Ulcer [description not available]	2.39	2
Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).	2.39	2
Anterior Circulation Transient Ischemic Attack [description not available]	2.38	2
Ischemic Attack, Transient Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)	2.38	2
Absence Seizure [description not available]	2.38	2
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	2.38	2
Curling Ulcer Acute stress DUODENAL ULCER, usually observed in patients with extensive third-degree burns.	1.98	1
Duodenal Ulcer A PEPTIC ULCER located in the DUODENUM.	1.98	1
Palsy [description not available]	1.98	1
Paralysis A general term most often used to describe severe or complete loss of muscle strength due to motor system disease from the level of the cerebral cortex to the muscle fiber. This term may also occasionally refer to a loss of sensory function. (From Adams et al., Principles of Neurology, 6th ed, p45)	1.98	1
Dementia Praecox [description not available]	2.89	4
Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.	2.89	4
Cervical Dystonia A common form of DYSTONIA due to involuntary sustained or spasmodic, repetitive muscle contractions in the neck region. According to the position of the twisted neck and head, cervical dystonia can be categorized as torticollis, laterocollis, retrocollis, and a combination of these abnormal postures.	2.69	3
Torticollis A symptom, not a disease, of a twisted neck. In most instances, the head is tipped toward one side and the chin rotated toward the other. The involuntary muscle contractions in the neck region of patients with torticollis can be due to congenital defects, trauma, inflammation, tumors, and neurological or other factors.	2.69	3
Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL).	1.99	1
Morphine Abuse [description not available]	1.99	1
Morphine Dependence Strong dependence, both physiological and emotional, upon morphine.	1.99	1
Intraocular Pressure The pressure of the fluids in the eye.	2	1
Academic Disorder, Developmental [description not available]	2	1
Age-Related Memory Disorders [description not available]	2	1
Learning Disabilities Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.	2	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2	1
Retinal Diseases Diseases involving the RETINA.	2.91	1
Alloxan Diabetes [description not available]	2	1
Glycosuria The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).	2	1
Carcinoma, Oat Cell [description not available]	2	1
Cancer of Lung [description not available]	2	1
Lung Neoplasms Tumors or cancer of the LUNG.	2	1
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	2	1
Drop Attack [description not available]	2	1
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	2.41	2
Syncope A transient loss of consciousness and postural tone caused by diminished blood flow to the brain (i.e., BRAIN ISCHEMIA). Presyncope refers to the sensation of lightheadedness and loss of strength that precedes a syncopal event or accompanies an incomplete syncope. (From Adams et al., Principles of Neurology, 6th ed, pp367-9)	2	1
Neuroleptic Malignant Syndrome A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)	2	1
Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.	2	1
Cough A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.	1.98	1
Carcinoma, Anaplastic [description not available]	1.97	1
Cancer of Colon [description not available]	1.97	1
Cancer of Kidney [description not available]	1.97	1
Sarcoma, Epithelioid [description not available]	1.97	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	1.97	1
Colonic Neoplasms Tumors or cancer of the COLON.	1.97	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	1.97	1
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	1.97	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	1.97	1
Adrenal Cancer [description not available]	1.97	1
Pheochromocytoma, Extra-Adrenal [description not available]	1.97	1
Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)	1.97	1
Decerebrate Posturing [description not available]	1.97	1

1,3-ditolylguanidine

Description

Cross-References

Synonyms (111)

Research Excerpts

Toxicity

Pharmacokinetics

Dosage Studied

Drug Classes (1)

Protein Targets (46)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (295)

Molecular Functions (99)

Ceullar Components (84)

Bioassays (294)

Research

Studies (349)

Study Types

1,3-ditolylguanidine

Description

Cross-References

Synonyms (111)

Research Excerpts

Toxicity

Pharmacokinetics

Dosage Studied

Drug Classes (1)

Protein Targets (46)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (295)

Molecular Functions (99)

Ceullar Components (84)

Bioassays (294)

Research

Studies (349)

Study Types

Related Drugs (273)

Related Conditions (125)